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Polymeric micelles represent a promising drug carrier system that has gained considerable 
attention due to its simplicity, small sizes, and ability to solubilize water-insoluble drugs and 
accumulate specifically in the tumors. However, most of them do not possess any biological 
activity by themselves. One interesting approach in the design of a carrier is to incorporate 
components in the carrier system itself that exhibit favorable biological activity, either 
counteracting the side effects caused by the loaded anticancer drugs, or promoting synergistic 
effect with the incorporated drug.  
We first developed a dual function carrier that is based on PEG-derivatized S-trans, trans-
farnesylthiosalicylic acid (FTS) (PEG5k-FTS2). FTS is a synthetic farnesylcysteine mimetic that 
acts as a potent and especially nontoxic Ras antagonist. In addition to retention of anti-Ras 
activity, PEG5k-FTS2 forms small-sized micelles that are capable of synergistic delivery of 
various hydrophobic agents. A further structure activity relationship (SAR) study was conducted 
in four PEG-FTS conjugates that vary in the molecular weight of PEG (PEG2K vs PEG5K) and 
the molar ratio of PEG/FTS (1/2 vs 1/4). We demonstrated that PEG5k-FTS4 formed the most 
stable mixed micelles with PTX among the four PEG-FTS conjugates.  
Next, we examined whether the performance of PEG5k-FTS2 can be further improved via 
incorporation of Fmoc, based on our recent discovery of Fmoc as a novel and potent drug-
interactive motif. Our data showed that introduction of an Fmoc at the interfacial region of 
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Xiaolan Zhang, Ph.D. 
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 v 
PEG5k-FTS2 led to a significant improvement in the drug loading capacity for a number of 
anticancer agents including paclitaxel (PTX), doxorubicin (DOX), curcumin, and etoposide. 
Finally, we established a reduction-sensitive delivery system by incorporation of an additional 
cleavable linkage (disulfide bond) into PEG5k-FTS2. We demonstrated that the incorporation of a 
disulfide linkage led to an enhanced release of FTS inside tumor cells, which was associated with 
an improved cytotoxicity against tumor cells.  
In summary, our data demonstrated that PEG-derivatized FTS can serve as dual 
functional carrier for the targeted delivery of therapeutic agents and contribute additional effects 
with the loaded anticancer drug. Our improved dual function carrier represents a simple and 
effective targeted drug delivery system for cancer. 
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 1 
1.0  INTRODUCTION 
1.1 NANOMEDICINE IN CANCER THERAPY 
Cancer is the leading cause of death in U.S., accounting for nearly 1 out of every 4 deaths. There 
were an estimated 14.1 million new global cancer incidences in 2012. This number is expected to 
increase to as many as 24 million within the next two decades [1]. Chemotherapy is a major 
therapeutic approach for the treatment of various types of cancers [2]. Nevertheless, clinical 
application of anticancer drugs is beleaguered by problems such as poor water solubility, short-
term physical stability, non-specificity, and high toxicity. First, administration of poorly water 
soluble drugs results in poor absorption and low bioavailability [3]. Second, the aggregation of 
water insoluble drugs could cause local toxicity. Third, anticancer drugs are usually small 
molecule drugs and are rapidly eliminated by liver and kidneys. Furthermore, nonspecific 
permeation into the entire body will lead to serious systemic toxicity. Currently, Cremophor 
EL/ethanol (1:1, v/v) and certain surfactants are used to improve the aqueous solubility of 
anticancer drugs [4].  However, Cremophor EL can cause hypersensitivity reactions, neuropathy, 
and other serious side effects. In addition, the utility of some commonly used surfactants is 
limited by their high critical micelle concentrations (CMCs), which raises the concern of drug 
precipitation or burst release of drug upon dilution in the blood [5].  The advent of 
nanotechnology brings promising alternatives in delivery of anticancer drugs [6].  A number of 
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macromolecular delivery systems such as polymeric micelles, liposomes, dendrimers and 
nanoparticles are under investigation to circumvent the limitations of current chemotherapies and 
improve the potential of the anticancer drugs [7]. These vehicles can carry various types of 
drugs, protect them from degradation, and prevent undesirable side effect on normal cells. 
Among the many studied delivery systems, polymeric micelles have gained considerable 
attention owing to their ease in preparation, small size (10-100 nm), and the ability to solubilize 
water-insoluble anticancer drugs and accumulate specifically at the targeted sites [8]. Currently, 
several polymeric micelles incorporated with anticancer agents, NK012, NK105, NK911, NC-
6004, SP1049C and Genexol-PM are under clinical evaluation [9], of which Genexol-PM has 
been approved by FDA for use in patients with breast cancer [10]. 
1.2 POLYMERIC MICELLES DELIVERY SYSTEM IN ONCOLOGY 
1.2.1 Polymeric micelle system 
Polymeric micelles usually have the unique core-shell architecture composed of distinct 
hydrophilic and hydrophobic domains, with the structure of the copolymer usually being a di-
block, tri-block, or graft copolymer [5]. The hydrophobic core provides a loading space for 
poorly water-soluble drugs and the hydrophilic shell allows polymeric micelle gain the stability 
in aqueous environment [11]. The hydrophobic block should have good biodegradability and 
provide excellent compatibility with the loaded drugs. Most commonly used polymers for 
hydrophobic core formation are polyesters and polyamides. The polyesters used include 
polycaprolactone (PCL), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and poly(lactide-
 3 
co-glycolide) (PLGA), all of which have been approved by the FDA for use in various clinical 
conditions [12-14]. Polyamides used include poly(L-histidine) (pHis), poly(L-aspartic acid) 
derivatives (pAsp) and poly(L-glutamic acid) derivatives (pGlu). These biocompatible polyesters 
and polyamides display gradual degradation kinetics inside the body with the degradation time 
ranging from days to weeks. Polymeric micelles generally possesse a very low CMC, ranging 
between 10-6-10-7 M, which is 1,000 times lower than those of low molecular weight surfactants. 
The stability (CMC) of polymeric micelles varies depending on the type and molecular weight of 
the hydrophobic block. Generally, the higher the molecular weight of a hydrophobic block is, the 
lower the CMC of the polymer will be.  
One unique type of polymeric micelles composed of cholic acid (CA) dendrimers as the 
hydrophobic block and poly (ethylene glycol) (PEG) as the hydrophilic domain have been 
developed by Lam’s group [15-17]. One such amphiphilic linear-dendritic copolymer PEG5K-
CA8 was composed of PEG, CA and lysine. They prepared paclitaxel (PTX) loaded PEG5K-
CA8 micelles with a tunable size of 20-60 nm. The most impressive properties of these micelles 
were excellent PTX loading capacity (35%, w/w of drug polymer ratio) and superior stability 
(longer than six months). This is due to the planar structure and the facial amphiphilicity of CA 
and the dendritic configuration of the hydrophobic core. These PTX loaded PEG-CA micelles 
showed preferential tumor accumulation and superior toxicity profiles and antitumor effects 
compared to Taxol (paclitaxel dissolved in Cremophor EL/ethanol (1:1, v/v) mixture) and 
Abraxane (Albumin-bound paclitaxel) that are two FDA approved formulations. [15]. This 
system has also been successfully applied to the delivery of doxorubicin (DOX) to tumor [18].  
Lipid-core micellar systems are another special type of polymeric micelles composed of 
lipid moieties as a hydrophobic block capped with a hydrophilic segment such as PEG. One 
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unique feature of lipid-core micelles is that they can be readily developed. In addition, the lipid-
core micelles have a relatively low CMC and demonstrate better stability compared to some 
commonly used lipid surfactants. Torchilin’s group first developed one such micellar system that 
is based on a PEG-phosphatidylethanolamine (PE) conjugate [19, 20]. These PEG-PE micelles 
had a CMC value that was at least a 100-fold lower than conventional surfactants. The presence 
of two fatty acyls contributes to an enhanced interaction between the lipid chains in the micelle 
core, which contributes to the high stability of drugs [19]. This system has been used for delivery 
of several hydrophobic drugs such as PTX, and camptothecin [20].  
Most micellar systems utilize PEG as the hydrophilic segment of the micelles. PEG is not 
biodegradable and does not form toxic metabolites. At the same time, PEG is commercially 
available in a variety of molecular weights from 1,000 to 20,000 Da. A prominent advantage of 
PEG modification is to impart in vivo longevity to drug carriers. First, PEG can reduce unwanted 
aggregation due to secondary interactions between polymeric particles. Second, the surface 
modification of a polymeric carrier with PEG can reduce the binding of plasma proteins and 
minimize nonspecific uptake by the reticuloendothelial system (RES), allowing the carrier to 
circulate in the blood for a long period of time. For example, amphiphilic diblock copolymers of 
PEG-b-poly(D,L-lactide–co-glycolide) (PEG-b-PLGA) showed prolonged blood circulation 
times compared to the conventional PLGA nanoparticles [14]. In addition to PEG, several other 
biocompatible hydrophilic polymers have been developed as steric protectors, such as poly 
(acryloyl morpholine) (PAM), phosphatidyl polyglycerols and polyvinyl alcohol (PVA). PAM is 
a non-ionic hydrophilic polymer with similar properties to PEG, which has good polymerization 
efficiency,  low toxicity and minimal immunological reactions in vivo [21]. PAM-modified 
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liposomes showed prolonged circulation in vivo [22]. Similarly, phosphatidyl polyglycerols or 
PVA coated liposomes showed prolonged circulating time in vivo [23]. 
1.2.2 Passive and active targeting via micellar system 
Targeted delivery of anticancer agents to tumor tissues not only increases the therapeutic effect 
of the drugs, but also reduces the toxic effects on normal tissue [24]. It is well known that tumor 
blood vessels have a high proportion of proliferating endothelial cells and that capillaries of 
tumor blood vessels become much more permeable than the capillaries of normal tissues [25]. In 
addition, tumor tissues generally have a defective lymphatic drainage system, leading to 
enhanced accumulation and retention of the macromolecules in tumors [26]. Therefore, given the 
long circulation times in blood, macromolecules and particles ranging from 10 to 500 nm are 
preferentially and passively accumulated at tumor and inflammatory tissues [27]. Since the 
passive targeting phenomenon was first discovered by Maeda et al. [28], numerous studies have 
substantiated that a nanocarrier with the size of 20-100 nm preferentially extravasates into solid 
tumor tissues owing to the leaky tumor vasculature [29, 30]. Besides, the effect of size on the 
biodistribution of polymeric micelles is organ- and tumor-type-dependent [31]. A recent study 
from Lam’s group compared the passive targeting of nanoparticles of different sizes in a 
subcutaneous model of human ovarian cancer xenograft. It was shown that particles with a size 
of 154 nm were significantly taken up by liver and lungs with limited accumulation at tumor 
sites. In contrast, particles of 17 and 64 nm were much more effective in passive targeting to the 
solid tumor [17]. Cabral and colleagues compared the targeting efficiency of polymeric micelles 
of different sizes (30, 50, 70, and 100 nm) in both highly and poorly permeable tumors. While all 
of the tested polymeric micelles penetrated highly permeable tumors in mice, only the 30 nm 
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micelles could penetrate poorly permeable pancreatic tumors to achieve an antitumor effect [32]. 
Thus, size optimization of polymeric micelles is one of the keys to successful passive targeting to 
different types of tumors [33].  
The further development of the targeted polymeric micelles involves attempting to add an 
active targeting moiety capable of recognizing receptors on the tumors, which will facilitate the 
specific interaction with the tumor cells and the subsequent intracellular delivery. Various types 
of ligands have been examined for active targeting including antibody, peptide, and small 
molecule ligands [34, 35]. Antibodies have been widely applied in terms of diversity of targets 
and specificity of interaction [35]. The accumulation of PEG-PE micelles can be enhanced in 
tumors through modification with anti-nucleosome monoclonal antibody 2C5 [36]. The use of 
small molecule ligands has the advantages of low cost and minimal immunogenicity. Folate 
receptor has been shown to be overexpressed in various types of cancers and folate-decorated 
delivery systems have been widely used for targeted delivery of various types of therapeutics to 
cancers [37]. Small molecules specific for prostate-specific membrane antigen (PSMA) is 
another promising ligand for active targeting of prostate cancers that overexpress PSMA [38]. 
Recently, there also has been an interest in exploring sigma receptor ligands for tumor imaging 
and targeted therapy. Sigma receptors are overexpressed in a variety of human tumors including 
non-small cell lung carcinoma (NSCLC), prostate cancer, melanoma, and breast cancer [39]. 
OA02-peptide was also used to prepare paclitaxel-loaded micelle targeted to α-3 integrin 
receptor to improve specific tumor-targeting to ovarian cancer cells [40]. Another interesting 
approach involves simultaneous incorporation of dual ligands into a nanomicellar system. It is 
reported that incorporation of dual ligands can enhance targeting efficiency and cytotoxicity in 
vitro and in vivo to A2780 ovarian carcinoma compared to single ligand-targeted micelles [41]. 
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1.2.3 Environmentally responsive micellar system 
In addition to targeted delivery, another important consideration in the design of an optimal 
delivery system is controlled or triggered drug release upon reaching the tumor tissues or 
intracellular delivery to tumor cells. Ideally, polymeric micelles should be designed such that 
they are stable in the circulation or in normal tissues, but, able to disintegrate and release the 
entrapped drugs in selective areas with unique environments such as in tumors and sites of 
inflammation. Tumors and inflammation sites usually exhibit mildly acidic pH. Acid-cleavable 
links such as acetal [42], orthoesters [43] and hydrazones [44] are stable at pH around 7.5 but are 
hydrolyzed rapidly at pH values of 6 and below [45]. Thus, pH-sensitive polymeric micelles with 
acid-labile linkages are prone to disintegration and release of loaded drugs at the tumor sites [46]. 
For example, Kataoka’s group reported that anticancer drugs, adriamycin (ADR), conjugated to 
the core forming block through a pH-sensitive hydrazone bond and the micelles released ADR 
both time- and pH-dependently as the pH value decreased from pH 7.4 to 3.0 [47]. Another 
interesting example of pH-sensitive micelle was shown by Bae’s group. They demonstrated that 
the cationic micelle was shielded by pH-sensitive anionic block copolymer to endow stability of 
micelle at pH 7.4. After the endocytosis of the micelle, the core was protonated in the acidic 
environment, which led to dissociation of the micelle and enhanced the delivery of drugs to the 
cytosol [48]. Redox-potential is another significant difference between the extra- and intra-
cellular environments. It has been found that the disulﬁde bond linkages, though sufﬁciently 
stable in low glutathione (GSH) concentrations (2-20 μM) in the body, show a rapid cleavage 
(over a time scale of a minutes to hours) under the reducing conditions of high intracellular GSH 
concentrations of 0.5-10mM [49]. Generally, the concentration of GSH in tumor tissues is 
several times higher than those of normal tissues. As a result, polymers containing disulﬁde 
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bonds show unique advantages of reduction-sensitive cleavage in the intracellular tumor 
environment via thiol-disulﬁde exchange reactions. The disulﬁde linkages in these reducible 
polymers are located in the main or side chains, and act as cross-linkers [50]. Other 
environmentally responsive systems such as temperature-sensitive, magnet-sensitive and 
ultrasound-sensitive system have also attracted increased attention recently. 
1.2.4 PEG-derivatized FTS-based dual functional micellar system 
S-trans, trans-farnesylthiosalicylic acid (FTS) is a synthetic farnesylcysteine mimetic that acts as 
a potent and especially nontoxic Ras antagonist [51]. Constitutively active Ras caused by 
mutation in the Ras family of proto-oncogenes is present in one-third of human cancers, with the 
highest incidence of mutational activation of Ras being detected in pancreatic (90%) and colon 
(50%) cancers [52]. Ras is also activated in cancer cells by other mechanisms. In particular, 
hyper activation of the epidermal growth factor receptor (EGFR) tyrosine kinase activity causes 
persistent activation of Ras and Ras-mediated signaling [53]. The activated form of Ras 
constitutively activates its downstream effectors, contributing to cell transformation [54]. FTS 
can inhibit both oncogenically activated Ras and growth factor receptor-mediated Ras activation, 
resulting in the inhibition of Ras-dependent tumor growth [55]. FTS can inhibit Ras transforming 
activity and reverse the transformed phenotype of Ras-transformed fibroblasts [56]. FTS has 
demonstrated significant reduction of Ras levels in a wide array of established cancer models and 
inhibition of tumor growth in animals with no adverse toxicity [57]. One major mechanism 
involves disrupting Ras membrane interactions by competing with Ras for binding to Ras-escort 
proteins, facilitating its degradation, and thus disrupting Ras protein signaling in the plasma 
membrane [58].  
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The major application of FTS in cancer treatment is in combination with other drugs of 
different mechanisms of action [59, 60]. The combined treatment of FTS and gemcitabine 
showed synergistic effects in inhibiting the growth of Panc-1 tumors, resulting in 81% reduction 
in tumor volume, which compared favorably to the individual drug treatments. In a clinical study, 
the combination of gemcitabine and FTS appeared to be well tolerated and exerted clinical and 
pharmacodynamics (PD) activity in pancreatic adenocarcinoma (PDA) [59]. The combination of 
FTS and a glycolysis inhibitor 2-deoxy-D-glucose (2-DG) had an effect on inhibition of cancer 
cell proliferation [60]. The combined application of histone deacetylase inhibitors, such as 
valproic acid (VPA) and FTS could synergistically inhibit the proliferation of cancer cells that 
express oncogenic K-Ras through down regulation of Ras and blocking the expression of 
survivin and aurora-A [61]. Kloog’s group demonstrated that FTS could chemosensitize Panc-1 
pancreatic cancer cells and SW 480 colon cancer cells to cytotoxic drugs without developing 
drug resistance [62]. FTS also exhibits anti-inflammatory activity. It can induce an increase in 
regulatory T cells in mouse splenocytes [63]. The combination of Celecoxib and FTS enhanced 
the anti-inflammatory activity on T cells independent of prostaglandin E2 production [64]. We 
have recently shown that FTS synergizes with curcumin in various types of cancers including 
breast and prostate cancer [65].  
FTS is poorly water soluble and also has limited oral bioavailability. Formulations for 
FTS have been rarely reported. One example is FTS-eluting ﬁbers that exhibited controlled 
release characteristics and effectively led to brain tumor growth inhibition [66]. We have 
recently shown that coupling of the hydrophobic FTS to PEG leads to a significant increase in 
water solubility [67]. Similar to PEG-embelin conjugates, PEG-FTS conjugates self-assemble to 
form micelles that are effective in solubilizing hydrophobic drugs. Again, this suggests that the 
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embelin conjugates with PEG5K work more effectively than the PEG3.5K counterparts and the 
PEG-FTS2 conjugates performed better than the PEG-FTS conjugates.  
1.2.5 Dual-functional micellar systems with drug-interactive domains 
Despite the various differences among the reported micellar systems, essentially all of them are 
designed to load drugs through the principle of hydrophobic/hydrophobic interactions. However, 
most of the existing drugs or drug candidates are only moderately hydrophobic agents. 
Carrier/drug incompatibility may contribute to limited drug loading capacity and decreased 
formulation stability. Park’s group has shown that inclusion of less hydrophobic and hydrogen 
bond-forming “hydrotropic motifs” into the hydrophobic domain of polymeric micelles 
significantly improved the compatibility of the core-forming blocks with the drugs that were not 
entirely hydrophobic/lipophilic, leading to significant improvement in both drug loading capacity 
and the colloidal stability of drug-loaded micelles [68]. However, this concept has not been 
tested in lipidic systems. Interestingly, pegylated surfactants with Vitamin E, embelin, or FTS as 
a hydrophobic domain, work significantly better than those with simple lipids as micellar 
formulations. The lipid core of our system is extremely hydrophobic due to the presence of two 
lipids, which might contribute considerably to an increase in hydrophobic interactions between 
the lipid chains. Further, Vitamin E, embelin, and FTS all have an interfacial aromatic ring 
linked to an acyl chain. Hydrophobic π-π interactions further elevated the hydrophobic 
interactions in the micelle’s core, which may contribute significantly to the improved 
formulation properties over surfactants with simple lipid chains. These studies highlight the 
benefit of introducing additional structural variables to traditional lipid-based excipients. We 
recently hypothesized that incorporation of a drug-interactive motif into a surfactant at the 
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interfacial region will introduce additional carrier/drug interaction mechanisms, which shall lead 
to improvement in both drug-loading capacity and formulation stability. This concept was tested 
with JP4-039, a mitochondria-targeted antioxidant and also a poorly water-soluble agent. We 
have developed a simple screening process to identify agents that have potential drug-interactive 
activities based on their ability to prevent the formation of JP4-039 crystals in aqueous solution 
[69]. Among several motifs screened, 9-Fluorenylmethoxycarbony (Fmoc) moiety, a functional 
group that is routinely used for amino acid protection, was the most potent one identified. We 
designed and synthesized a micelle-forming PEG-lipopeptide conjugate with a lysine branching 
segment and two Fmoc groups located at the interfacial region, and two oleoyl chains as the 
hydrophobic core. We found that incorporation of Fmoc motifs into a PEG-lipopeptide conjugate 
led to a significantly improved formulation with respect to both JP4-039 loading capacity and the 
stability of JP4-039-loaded micelles. We then demonstrated that this micellar formulation can 
also be effectively used in formulating 7 drugs of diverse structures including probucol, 
niclosamide, JP4-039, progesterone, cyclosporin A, nifedipine, and griseofulvin [70]. These data 
strongly suggest that α-Fmoc behaves as a “formulation chemophor” or a structural unit capable 
of interacting with many pharmaceutical agents. This has led us to testing whether incorporation 
of a Fmoc motif can further improve the performance of the PEG5K-FTS2 micellar system. 
Indeed, this approach has led to a 3.9- and 3-fold increase in drug loading capacity for PTX and 
DOX, respectively. In addition, the stability of drug-loaded formulations was significantly 
improved [71]. More studies on the in vitro and in vivo characterization of the improved dual-
functional carrier are ongoing in our laboratory. 
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2.0  PEG-FARNESYLTHIOSALICYLATE CONJUGATE AS A NANOMICELLAR 
CARRIER FOR DELIVERY OF PACLITAXEL DELIVERY 
2.1 ABSTRACT 
S-trans, trans-farnesylthiosalicylic acid (FTS) is a synthetic small molecule that acts as a potent 
and especially nontoxic Ras antagonist. It inhibits both oncogenically activated Ras and growth 
factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor 
growth. In this work, an FTS conjugate with poly(ethylene glycol) (PEG) through a labile ester 
linkage, PEG5K-FTS2(L), was developed. PEG5K-FTS2 conjugate readily forms micelles in 
aqueous solutions with a critical micelle concentration of 0.68 μM, and hydrophobic drugs such 
as paclitaxel (PTX) could be effectively loaded into these particles. Both drug-free and PTX-
loaded micelles were spherical in shape with a uniform size of 20−30 nm. The release of PTX 
from PTX-loaded PEG5K-FTS2 micelles was significantly slower than that from Taxol 
formulation. In vitro cytotoxicity studies with several tumor cell lines showed that PEG5K-FTS2 
(L) was comparable to FTS in antitumor activity. Western immunoblotting showed that total Ras 
levels were downregulated in several cancer cell lines treated with FTS or PEG5K-FTS2 ( L). The 
micellar formulation of PTX exhibited more in vitro cytotoxic activity against several tumor cell 
lines compared with free PTX, suggesting a possible synergistic effect between the carrier and 
the codelivered drug. The antitumor activity of the PTX loaded PEG5K-FTS2 (L) micelles in a 
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syngeneic murine breast cancer model was found to be significantly higher than that of Taxol, 
which may be attributed to their preferential tumor accumulation and a possible synergistic effect 
between PEG5K-FTS2 carrier and loaded PTX. 
2.2 BACKGROUND 
Clinical application of PTX in cancer therapy is limited by problems such as low water 
solubility, lack of tissue-specificity and high toxicity [72, 73]. A number of macromolecular 
delivery systems are under investigation to circumvent these limitations and improve the 
potential of the anticancer drug [5, 7]. However, it remains a challenge to design a vehicle that 
can carry sufficient amount of drugs and efficiently overcome various physiological barriers to 
reach the tumor tissues [74]. Micelles with a nanoscopic supramolecular core-shell structure, are 
one such carrier of choice. It has been established that a nanocarrier with the size of 20-100 nm 
preferentially extravasates into solid tumor tissues owing to the leaky tumor vasculature [29, 30].  
Additionally, a hydrophilic polymer (PEG) grafted onto the surface prolongs blood circulation 
times of the micelles due to the inhibition of nonspecific uptake by the reticuloendothelial system 
(RES) [33, 75]. However, for most delivery systems, the vehicles themselves rarely possess 
pharmacological activity. The use of “inert” excipients that lack therapeutic activity not only 
adds to the cost but also potentially imposes safety issues [76]. 
An interesting strategy to the design of multifunctional nanocarriers is to use the highly 
water-insoluble drug itself as the hydrophobic region of polymeric micelles. One example is 
pegylated vitamin E, D-α-tocopheryl poly(ethylene glycol) succinate (Vitamin E TPGS or 
TPGS) [77-79]. Vitamin E itself shows antitumor effect against different types of cancers and 
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vitamin E TPGS is effective in solubilizing various hydrophobic drugs. Synergistic effects 
between the TPGS-based carriers and delivered anti-cancer drugs have been demonstrated [8]. 
Recently our group reported another dual-functional carrier that is based on PEG-
derivatized embelin [80]. Embelin shows antitumor activity in various types of cancers through 
various mechanisms such as the inhibition of the activity of X-linked inhibitor of apoptosis 
protein (XIAP) [81]. PEG-modified embelin shows significantly increased solubility (> 200 
mg/mL) in aqueous solution. More importantly, PEG-embelin forms micelles that effectively 
solubilize various types of hydrophobic drugs such as PTX. Significantly improved antitumor 
activities were demonstrated for PTX formulated in PEG-embelin micelles both in vitro and in 
vivo [80]. 
In this study, we design a self-assembling nanomicellar system that is based on PEG-
derivatized farnesylthiosalicylic acid (FTS) for targeted delivery of PTX. FTS is a first-in-class 
direct Ras antagonist designed to inhibit overactive cell growth in cancers caused by various Ras 
proteins [51]. Permanently active Ras caused by mutation in the Ras family of proto-oncogenes, 
is present in one-third of human cancers, with the highest incidence of mutational activation of 
Ras being detected in pancreatic (90%) and colon (50%) cancers [82, 83]. FTS has demonstrated 
significant reduction of Ras levels in a wide array of established cancer models without 
observable side effects [62]. One major mechanism involves affecting membrane interaction by 
inducing dislodgement of Ras protein from its anchorage domains, facilitating its degradation, 
and thus disrupting Ras protein signaling in the plasma membrane [55, 84]. FTS is poorly water-
soluble [66] and PEGylation is designed to improve its solubility. At the same time, the PEG-
FTS conjugate forms micelles, which could be applied as an ideal carrier for hydrophobic drugs 
to improve their efficiency and safety profiles. Additionally, the carrier materials can potentially 
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promote synergistic effects with the co-delivered anti-cancer drug. The PEG5K-FTS2 conjugate 
was synthesized and characterized for its structure and molecular weight. We further 
characterized the biophysical properties of drug-loaded micelles including particle size, loading 
capacity, and in vitro drug release kinetics. Finally, the in vitro and in vivo antitumor activity of 
PTX/PEG-FTS was investigated. 
2.3 EXPERIMENTAL PROCEDURES 
2.3.1 Materials 
Paclitaxel (98%) was purchased from AK Scientific Inc. (CA, USA). FTS was synthesized and 
purified following a published literature [85]. Pan Ras Ab (Ab-3) was purchased from 
Calbiochem (La Jolla, CA). HRP-labeled goat anti-mouse IgG and the ECL chemiluminescence 
kit were purchased from Amersham Biosciences (Piscataway, NJ, USA). Dulbecco’s phosphate 
buffered saline (DPBS) was purchased from Lonza (MD, USA). Poly(ethylene glycol) methyl 
ether (MeO-PEG-OH, Mw=5000 kDa), dimethyl sulfoxide (DMSO), 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide (MTT), trypsin-EDTA solution, Triton X-100, and 
Dulbecco’s Modified Eagle’s Medium (DMEM) were all purchased from Sigma-Aldrich (MO, 
USA). Fetal bovine serum (FBS) and penicillin-streptomycin solution were from Invitrogen 
(NY, USA). 
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2.3.2 Synthesis of PEG5K-FTS2(L) and PEG5K-FTS2(S) conjugate 
PEG5K-FTS2(L) conjugates with a labile linkage were prepared via solution phase condensation 
reactions from MeO-PEG-OH with a molecular weight of 5000 (Figure 1). We started with 
synthesizing carboxyl terminated PEG monomethyl ether (MeO-PEG5k-COOH) from MeO-
PEG5k-OH (1 eq.) by a facile chemical reaction with succinic anhydride (5 eq.) and 4-
(dimethylamino) pyridine (DMAP 5 eq.) in pyridine according to a reported method [80]. To 
obtain two hydroxyl group terminated PEG monomethyl ether (MeO-PEG5k-(OH)2), 
diethanolamine  (3 eq.) was coupled onto the carboxylic group of MeO-PEG5k-COOH (1 eq.) 
using N-hydroxysuccinimide (NHS 3.6 eq.)/dicyclohexylcarbodiimide (DCC 3.6 eq.) as coupling 
agent in chloroform overnight. The polymer was precipitated and washed by ice-cold ether three 
times, and concentrated under vacuum. MeO-PEG5k-(OH)2, FTS, DCC and DMAP were then 
dissolved in  chloroform with a molar ratio of 1: 6: 3: 0.3 and allowed to react overnight at room 
temperature. The solution was filtered and precipitated in ice-cold diethyl ether and ethanol twice 
respectively, and concentrated under vacuum. The powder was then dissolved in water and 
filtered through a filter with a pore size of 0.2 m. The final product was obtained by 
lyophilizing the filtrate. At the same time, we also prepared a PEG5K-FTS2(S) conjugate (Figure 
2) with a stable amide linkage. MeO-PEG5k-OH and (S)-2,6-Bis-tert-
butoxycarbonylaminohexanoic acid (Boc-Lys(Boc)-OH) were dissolved in chloroform together 
with DCC and DMAP with a molar ratio of 1:3:1.5:0.3 and the mixture was left to react 
overnight at room temperature. PEGylated molecules were recovered from the mixture through 
three cycles of dissolution/reprecipitation with chloroform and ether, respectively. Boc groups 
were removed via the treatment with 50% (v/v) trifluoroacetic acid (TFA) in chloroform, and 
PEGylated molecules were precipitated and washed with ice-cold ether. Finally, FTS was 
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coupled onto the N terminal group of MeO-PEG5k-Lys-(NH2)2 (1 eq.) via NHS (3.6 eq.)/DCC 
(3.6 eq.) as described above. After the reaction was completed, the solution was precipitated in 
cold ether. PEG5K-FTS2(S) was similarly purified as that for PEG5K-FTS2(L).  
 
 
Figure 1. Synthesis scheme of PEG5K-FTS2 (L) conjugate 
 
 
Figure 2. Synthesis scheme of PEG5K-FTS2 (L) conjugate 
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2.3.3 Preparation of PTX loaded and drug-free micelles 
PTX (10 mM in chloroform) and PEG5K-FTS2 (10 mM in chloroform) were mixed with various 
carrier/drug ratios. The organic solvent was removed by nitrogen flow to form a thin film of 
drug/carrier mixture. The film was dried under vacuum for 1 h to remove the remaining solvent. 
DPBS was added to hydrate the thin film and the drug-loaded micelles were formed. The drug-
free micelles were similarly prepared as described above.  
2.3.4 Characterizations of PTX loaded and drug-free micelles 
The particle size and zeta potential of micelles were measured by a Zetasizer (DLS) (Zetasizer 
Nano ZS instrument, Malvern, Worcedtershire, UK). The micelle concentrations were kept at 1 
mg/mL. The morphology and size distribution of drug-free or PTX-loaded PEG5K-FTS2 micelles 
were observed using transmission electron microscopy (TEM). A copper grid with Formvar was 
used. The copper grid was immersed in a drop of sample solution and stained with 1% uranyl 
acetate. Imaging was performed at room temperature on JEOL JEM-1011.  
The critical micelle concentration (CMC) of PEG5K-FTS2 was determined using pyrene 
as a fluorescence probe [13]. PEG5K-FTS2 was prepared in chloroform at 1.2 mg/mL and various 
amounts were added to 9 separate vials, respectively. Then 10 μl of 1.8 × 10−4 M of pyrene in 
chloroform was added to each vial and the solution was mixed well. The organic solvent was 
removed by nitrogen flow to form a thin film. Finally, 3 ml Milli-Q water was added to each vial 
and the final pyrene concentration was 6×10-7 M with PEG5K-FTS2 concentrations ranging from 
0.0001 to 0.5 mg/mL. The vials were kept on a shaker at 37℃ for 24 h to reach equilibrium prior 
to fluorescence measurement. The excitation spectra were scanned from 310 to 350 nm at a fixed 
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emission wavelength of 390 nm by Synergy H1 Hybrid Multi-Mode Microplate Reader 
(Winooski, VT). The pyrene ﬂuorescence intensity ratio I338/I334 in the excitation spectra was 
analyzed for calculation of CMC.  
The drug loading efficiency was quantified by high performance liquid chromatography 
(HPLC) (Alliance 2695-2998 system). The reverse phase Lichrospher® 100 RP-18 (5 μm）
column was used and the mobile phase consisted of methanol/water (80: 20 v/v). The flow rate 
was set at 0.8 mL/min and the column effluent was detected at 227 nm with a UV/Vis detector. 
Drug loading capacity (DLC) and drug loading efficiency (DLE) were calculated according to 
the following equation: 
DLC (%) = [weight of drug used/(weight of polymer + drug used)] ×100% 
DLE (%) = (weight of loaded drug/weight of input drug) ×100% 
2.3.5 In vitro drug release study 
Release of PTX from PTX-loaded PEG5K-FTS2 micelles was performed following a method 
described previously [80]. Briefly, 3 mL of PTX-loaded PEG5K-FTS2 micelles or Taxol (1 mg 
PTX/mL) solution was placed in a dialysis bag (MWCO = 12 KDa, Spectrum Laboratories) that 
was incubated in 200 mL DPBS (PH = 7.4) containing 0.5% (w/v) Tween 80 at 37 °C with 
gentle shaking. The concentration of PTX remaining in the dialysis tubes at designated time 
points was measured by HPLC with the detection wavelength at 227 nm. Values were reported 
as the means from triplicate samples.  
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2.3.6 Hemolytic effect of PEG5K-FTS2 micelles 
A hemolysis was assessed using fresh blood collected through cardiac puncture from rats.  The 
red blood cells (RBCs) were collected by centrifugation at 1500 rpm for 10 min at 4 ℃. After 
washing three times with PBS, RBCs were diluted to a final concentration of 2% w/v in PBS. 
One mL of diluted RBC suspension was mixed with various concentrations (0.2 and 1.0 mg/mL) 
of PEG5k-FTS2 and PEI, respectively, and then incubated at 37 ℃ in an incubator shaker for 4 h. 
The mixtures were centrifuged at 1500 rpm for 10 min at 4 ℃, and 100 L of supernatant from 
each sample was transferred into a 96-well plate. The release of hemoglobin was determined by 
absorbance at 540 nm using a microplate reader. RBCs incubated with Triton X-100 (2%) and 
PBS were used as the positive and negative controls, respectively. The percentage of hemolysis 
of RBCs was calculated as (ODsample-ODnegative control)/ (ODpositive control-ODnegative control) × 100% 
2.3.7 Cell culture 
DU145 and PC-3 are two androgen-independent human prostate cancer cell lines. 4T1.2 is a 
mouse metastatic breast cancer cell line. HCT-116 is a human colon carcinoma cell line. All cell 
lines were cultured in DMEM containing 5% FBS and 1% penicillin-streptomycin at 37 ℃ in a 
humidified 5 % CO2 atmosphere. 
2.3.8 In vitro cell cytotoxicity 
For cytotoxicity measurement, DU145 (2000 cells/well), PC-3 (2000 cells/well), 4T1.2 (1000 
cells/ell) or HCT-116 (1000 cells/well) were seeded in 96-well plates. After 24 h of incubation in 
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DMEM with 5% FBS and 1% streptomycin-penicillin, the old medium was removed and the 
cells were incubated for 72 h in the presence of indicated concentrations of PTX (free or 
formulated in PEG5K-FTS2 micelles). Twenty µL of 3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) in DPBS (5 mg/mL) was added to each well and cells were 
further incubated for 4 h. MTT formazan was solubilized by DMSO. The absorbance in each 
well was measured by a microplate reader at a wavelength of 550 nm with a reference 
wavelength at 630 nm. Untreated groups were used as controls. Cell viability was calculated as 
[(ODtreat-ODblank)/ (ODcontrol-ODblank) × 100%]. The cytotoxicity of PEG5K-FTS2(L) or PEG5K-
FTS2(S) alone was similarly examined. 
2.3.9 Western immunoblotting 
Cells were grown in dishes in medium containing 5 % FBS, in the presence of 0.1 % DMSO 
(control) or indicated concentrations of FTS, PEG5K-FTS2(L), and PEG5K-FTS2(S) respectively. 
Following treatment for 48 h, cells were washed with ice-cold PBS twice and solubilized in lysis 
buffer. The lysates were centrifuged at 14000 for 10 min after a 10-min incubation on ice. 
Samples with equal amounts of total cellular proteins were subjected to 15% sodium 
dodecylsulfate polyacryl amide gel electrophoresis (SDS-PAGE) before proteins were 
transferred to nitrocellulose membranes. The membranes were incubated with primary antibody 
in 5% non fat dry milk dissolved in DPBS with 0.1% Tween 20 (PBST) overnight at 4°C. After 
washing three times with PBST, the membranes were incubated with secondary antibody at a 
final dilution of 1:10,000 in PBST for 1 h at room temperature. After washing three times with 
PBST, bound antibodies were detected by chemiluminescence. β-actin was used as a loading 
control. 
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2.3.10 Animals  
Female BALB/c mice, 10-12 weeks in age, were purchased from Charles River (Davis, CA). All 
animals were housed under pathogen-free conditions according to AAALAC guidelines. All 
animal-related experiments were performed in full compliance with institutional guidelines and 
approved by the Animal Use and Care Administrative Advisory Committee at the University of 
Pittsburgh. 
2.3.11 In vivo therapeutic study 
A syngeneic murine breast cancer model (4T1.2) was used to examine the therapeutic effect of 
different formulations of PTX. 1 x 105 4T1.2 cells in 200 L PBS were inoculated 
subcutaneously (s.c) at the right flank of female BALB/c mice. Treatments were started when 
tumors in the mice reached a tumor volume of ~50 mm3 and this day was designated as day 1. 
On day 1, these mice were randomly divided into six groups (n=5) and administered i.v. with 
PBS (control), free PEG5K-FTS2(S) micelles, Taxol (10 mg PTX/kg), PTX-loaded PEG5K-
FTS2(L) (10 and 20 mg PTX/kg), and PTX-loaded PEG5K-FTS2(S) (10 mg PTX/kg), respectively 
on days 1, 4, 6, 8, 11 and 13. Free PEG5K-FTS2(L) micelles were given at the equivalent dosage 
of the carrier in the group of PTX-loaded PEG5K-FTS2(L) micelles (10 mg PTX/kg). Tumor sizes 
were measured with digital caliper three times a week and calculated by the formula: (L×W2)/2, 
where L is the longest, W is the shortest in tumor diameters (mm). To compare between groups, 
relative tumor volume (RTV) was calculated at each measurement time point (where RTV equals 
to the tumor volume at a given time point divided by the tumor volume prior to first treatment). 
Mice were sacrificed when tumor volume reached 2000 mm3.  
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2.3.12 Statistical analysis 
In all statistical analysis, the significance level was set at a probability of P < 0.05. All results 
were reported as the mean ± standard error (SEM) unless otherwise indicated. Statistical analysis 
was performed by Student’s t-test for two groups, and one-way ANOVA for multiple groups, 
followed by Newman-Keuls test with a P < 0.05.  
2.4 RESULTS   
2.4.1 Synthesis of PEG5K-FTS2(L) and PEG5K-FTS2(S) conjugates 
PEG5K-FTS2(L) conjugates, containing two molecules of FTS coupled to one molecule of PEG 
via a labile ester linkage, were developed by solution phase condensation reactions. 1H NMR 
spectra of PEG5K-FTS2(L) conjugate are shown in Figure 3, with signals at 3.63 ppm attributable 
to the methylene protons of PEG. Carbon chain signals and benzene ring signals of FTS were 
located at 1.5-2.2 ppm and 7-8 ppm, respectively. A peak appearing at δ 4.5 from a –CH2CH2N 
group confirmed the conjugation of FTS with PEG. The signal ratio of the protons on PEG chain 
to the protons on -C=C(CH3)2 group of FTS is around 1:8 (Figure 3), which suggested that two 
FTS molecules were attached onto the PEG chain. The molecular weight of the PEG5K-FTS2(L) 
conjugate measured by MALDI-TOF Mass Spectra is close to the theoretical value (5867) 
(Figure 4), further confirming that two FTS molecules were conjugated to one molecule of PEG. 
We also synthesized a PEG5K-FTS2(S) conjugate in which FTS was coupled onto PEG chain via 
a stable amide linkage.  
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Figure 3. 1H NMR spectra of PEG5K-FTS2(L) conjugate 
 
 
 
Figure 4. MALDI-TOF mass spectra of PEG5K-FTS2(L) conjugate 
2.4.2 Characterizations of micelles 
The PEG5K-FTS2 conjugates readily formed micelles in aqueous solution. Dynamic light 
scattering (DLS) measurements showed that these micelles had hydrodynamic sizes around 22 
nm at the concentration of 20 mg/mL (Figure 5A). TEM revealed spherical particles with 
uniform size distribution (Figure 5B). The size observed by TEM shows good agreement with 
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that determined by DLS. PTX could be effectively loaded into PEG5K-FTS2 micelles. The size 
and size distribution were not significantly affected when PTX was loaded into micelles at a drug 
concentration of 1 mg/mL and a carrier/drug ratio of 5/1 (m/m) (Figures 5C and D).  
 
 
Figure 5. Particle size distribution of free drug PEG5K-FTS2 (A) and PTX/PEG5K-FTS2 micelles 
(C). TEM images of free drug PEG5K-FTS2 (B) and PTX/PEG5K-FTS2 micelles (D). 
 
The CMC of PEG5K-FTS2 micelles was measured using pyrene as a fluorescence probe. 
When the concentration of the PEG5K-FTS2 reached the CMC, there is a major change for the 
I338/I334 value due to the transfer of pyrene from polar micro-environment to non-polar micro-
environment caused by the formation of micelles. The CMC of the PEG5K-FTS2 micelles was 
determined to be 0.68 µM (Figure 6). 
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Figure 6. Plot of the ratio of I338/I334 from fluorescence spectra as a function of logarithm 
concentration of PEG5K-FTS2 micelles.  
Pyrene was used as molecular probe ([Pyrene]=6.0×10-7 M). 
 
Table 1 shows the size of PTX-loaded micelles at different carrier/drug molar ratios. All 
of them had small size of around 20 nm. With increases in the input molar ratio of PEG5K-
FTS2/PTX, the sizes of the PTX-loaded micelles were more close to that of drug-free micelles. 
The drug loading efficiency of PEG5K-FTS2 micelles was over 90% at various carrier/drug ratios 
examined (Table 1).  
 
Table 1. Physicochemical characterization of free drug and PTX-loaded PEG5K-FTS2 micelles 
Micelles Molar 
ratio 
Conc. of PTXa  
(mg/mL) 
Sizeb  
(nm) 
PDIc DLEd 
(%) 
DLCe 
(%) 
PEG5K-FTS2 - - 17.61± 0.9 0.201 - - 
PEG5K-FTS2 :PTX 3.75 :1 1 24.93± 1.2 0.354 90.6 3.73 
PEG5K-FTS2 :PTX 5 :1 1 25.63± 3.4 0.234 97.6 2.82 
PEG5K-FTS2 :PTX 7.5 :1 1 22.27± 0.6 0.268 98.0 1.90 
PEG5K-FTS2 :PTX 10 :1 1 20.17± 0.2 0.189 96.2 1.43 
aPTX concentration in micelle was kept at 1 mg/mL. Blank micelle concentration was 20 mg/mL. 
Values repotted are the mean ± SD for triplicate samples.  
bMeasured by dynamic light scattering particle sizer.  
cPDI = polydispersity index.  
dDLC = drug loading capacity. eDLE = drug loading efficiency.  
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2.4.3 In vitro drug release study 
The profile of PTX release was examined by a dialysis method and compared to that of Taxol. 
For the initial 8 h, about 41.2 % of PTX was released from the Taxol formulation while only 
16.7 % of PTX was released from the PTX-loaded PEG5K-FTS2 micelles (Figure 7). PTX 
release from PEG5K-FTS2 micelle formulation was significantly slower compared to Taxol 
formulation during the entire experimental period. The T1/2 of PTX release is 95.4 h for PEG5K-
FTS2 formulation, which is significantly longer than that for Taxol formulation (17.6 h). 
 
Figure 7. Cumulative PTX release profile from Taxol and PEG5K-FTS2 micelles. 
2.4.4 Hemolytic effect of PEG5K-FTS2 micelles 
Detrimental interaction of micelles with blood constituents such as RBCs must be avoided when 
these micelles are injected into the blood circulation as a carrier for drug delivery [86]. Figure 8 
shows the hemolytic activities of drug free PEG5K-FTS2 micelles and polyethylenimine (PEI), a 
cationic polymer known to have significant hemolytic effect [86]. PEI induced hemolysis in a 
dose-dependent manner. In contrast, free PEG5K-FTS2 micelles did not show any detectable 
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hemolytic activities at the same experimental concentrations, suggesting that is safe to administer 
the product intravenously without concern for hemolysis.  
 
Figure 8. In vitro hemolysis assay of empty PEG5K-FTS2 micelles. 
Compared with PEL with two different concentrations (0.2, 1 mg/mL). Value reported are the 
mean ± SD for triplicate samples. 
2.4.5 Western immunoblotting 
We incubated HCT-116 or 4T1.2 cells with various concentrations of FTS, PEG5K-FTS2(L) and 
PEG5K-FTS2(S) for 48 h, respectively, and the protein expression levels of Ras in the cells were 
examined by Western immunoblotting with pan anti-Ras Ab. As shown in Figure 9, FTS 
treatment caused a reduction in the total amount of cellular Ras in both cell lines. These results 
are consistent with the known action of FTS as a Ras inhibitor. PEG5K-FTS2(L) was comparable 
to free FTS in reducing the protein levels of Ras in the treated cells. In contrast, PEG5K-FTS2(S) 
showed minimal effect at the same FTS concentration. 
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Figure 9. Effect of FTS, PEG5K-FTS2(L) and PEG5K-FTS2(S) on total Ras expression analyzed 
by Western blot.  
Cells grown in dishes in medium containing 5% FBS, in the presence of 0.1% DMSO (control) 
or in the presence of 5 µM of PEG5K-FTS2(L), PEG5K-FTS2(S) and 10 µM of FTS for 48 h. Total 
cell lysate was subjected to Western blot analysis. β-actin was used as a loading control. 
2.4.6 In vitro cytotoxicity 
Several cancer cell lines were included in the cytotoxicity studies including murine breast cancer 
cells 4T1.2, human colon carcinoma cell line HCT-116, and two human prostate cancer cell lines 
PC-3 and DU145. Figure 10A shows the cytotoxicity of two PTX-free micelles, PEG5K-FTS2(L) 
and PEG5K-FTS2(S), in comparison with free FTS in 4T1.2 tumor cells. Free FTS inhibited the 
tumor cell growth in a concentration-dependent manner.  Conjugation of FTS to PEG via a labile 
ester linkage resulted in only a slight decrease in antitumor activity. In contrast, a similar 
conjugate with a stable amide linkage [PEG5K-FTS2(S)] was significantly less active compared to 
both free FTS and PEG5K-FTS2 (L). A similar result was obtained in human colon cancer cells, 
HCT-116 (Figure 10B). 
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Figure 10. Cytotoxicity of free FTS, PEG5K-FTS2(L) and PEG5K-FTS2(S) in 4T1.2 mouse breast 
cancer cell line (A) and HCT-116 human colon carcinoma cell line (B).  
 
 
Figure 11. Cytotoxicity of free PTX, free PEG5K-FTS2(L) and PTX/PEG5K-FTS2(L) micelles 
against different cancer cell lines. 
Including the 4T1.2 mouse breast cancer cell line (A), two androgen-independent human prostate 
cancer cell lines DU145 (B) and PC-3 (D), and human colon carcinoma HCT-116 cell line (C). 
Cells were treated for 72 h and cytotoxicity was determined by MTT assay. Values reported are 
the means ± SD for triplicate samples.  
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Figure 11A shows the cytotoxicity of free PTX (in DMSO) and PTX formulated in PEG5K-
FTS2(L) or PEG5K-FTS2(S) micelles in 4T1.2 tumor cells. Free PTX inhibited the tumor cell 
growth in a concentration dependent manner. Delivery of PTX via PEG5K-FTS2(L) micelles led 
to a significant increase in the cytotoxicity. Interestingly, PTX formulated in PEG5K-FTS2(S) was 
less active than free PTX. Similar results were obtained in other tumor cell lines including 
DU145 (Figure 11B), PC-3 (Figure 11C), and HCT-116 (Figure 11D). 
2.4.7 In vivo therapeutic study 
The in vivo therapeutic activity of PTX formulated in PEG5K-FTS2 micelles was investigated in a 
syngeneic murine breast cancer model (4T1.2). As shown in Figure 12A, free PEG5K-FTS2 
micelles alone showed no effects in inhibiting the tumor growth at the concentration used. The 
other groups treated with different PTX formulations showed varied levels of antitumor effects 
and they were ranked as PTX/PEG5K-FTS2(L) > PTX/PEG5K-FTS2(S) > Taxol at the same dose 
of 10 mg PTX/kg. By day 13, the relative tumor volume (RTV) was 15.1 for Taxol, while the 
RTVs for PTX/PEG5K-FTS2(S) and PTX/PEG5K-FTS2(L) were 13.3 and 9.6, respectively. 
Increasing the PTX dosage to 20 mg/kg in PTX-loaded PEG5K-FTS2(L) formulation resulted in a 
further improvement in antitumor activity with a RTV of 5.2. No significant changes in body 
weight were noted in all treatment groups compared to PBS control group (Figure 12). 
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Figure 12. Enhanced antitumor activity of PTX formulated in PEG5K-FTS2(L) and PEG5K-
FTS(S) micelles.  
BABL/c mice were inoculated s.c. with 4T1.2 cells (1 x 105 cells/mouse). Five days later, mice 
received various treatments twice a week and tumor growth was monitored and plotted as 
relative tumor volume (mm3). (A) The changes of relative tumor volume. (B) Body weight after 
administration. P < 0.001 (PTX/PEG5K-FTS2 (L) vs. Taxol). N = 5.  
2.5 DISCUSSION 
In this study, we developed a micellar system that is based on PEG-derivatized FTS. FTS is an 
antagonist of Ras and is currently being evaluated as a new therapy for the treatment of various 
types of cancers that are associated with Ras mutations and elevated levels of Ras activity. A 
major feature with FTS is its excellent safety profile compared to other chemotherapeutic agents 
[58, 83, 87]. This will render PEG-FTS micelles a safe delivery system for in vivo delivery of 
various types of anticancer agents including FTS itself. 
One major advantage of PEG-FTS micellar system is its very small size (~20 nm). It is 
generally regarded that particles in the size range of 10 ~ 200 nm can be passively targeted to 
tumors via the leaky tumor vasculature [28, 88, 89]. However, recent studies have shown that the 
size of the particles needs to be below 50 ~ 60 nm for them to effectively reach poorly 
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vascularized tumors [17, 32]. The small size of PEG-FTS micelles will allow effective passive 
targeting to various types of cancers including those with poorly developed tumor vasculature. 
In vitro release study showed significantly slower release kinetics for PTX formulated in 
PEG5K-FTS2 micelles compared to Taxol formulation (Figure 7). This might be due to a more 
effective drug/carrier interaction for PTX/PEG5K-FTS2 mixed micelles. FTS has a benzene ring 
and an acyl chain. In addition to hydrophobic interaction with PTX, the - stacking and the 
hydrogen bonding also contribute to the overall carrier/PTX interaction. The close proximity of 
two FTS molecules in PEG5K-FTS2 conjugate shall enhance the interaction of the carrier with 
PTX. Indeed, a PEG-FTS conjugate of 1:1 molar ratio was much less active than PEG5K-FTS2 in 
forming stable mixed micelles with PTX (data not shown).  More studies are needed to better 
define the mechanism of drug/carrier interactions for PTX/PEG5K-FTS2 mixed micelles. 
PEG5K-FTS2(L) alone was much more active than PEG5K-FTS2(S) in antitumor activity in 
both 4T1.2 and HCT-116 cell lines (Figure 10). It is unlikely that this is attributed to differences 
in the surface activity of the two conjugates as both showed minimal hemolytic activity at the 
concentrations that were much higher than those used in the cytotoxicity study. It is likely that 
FTS is much more readily released from PEG5K-FTS2(L) by esterases following intracellular 
delivery. The cytotoxicity data agree with Western blotting in which PEG5K-FTS2(L) was more 
active than PEG5K-FTS2(S) in reducing the protein expression levels of Ras in treated tumor cells 
(Figure 9). 
In addition to more potent antitumor activity by itself, PEG5K-FTS2(L) was also more 
active than PEG5K-FTS2(S) in mediating PTX cytotoxicity to tumor cells (Figure 11). At the 
concentrations used for PTX delivery, both PEG5K-FTS2(L) and PEG5K-FTS2(S) were not active 
in killing tumor cells by themselves. This is consistent with published works [56, 90, 91] and our 
 34 
own data (Figure 10) that FTS works at high M concentrations. It remains to be determined if, 
at suboptimal concentrations as those in cells treated with PEG5K-FTS2(L), the released FTS 
could synergize with PTX in the overall antitumor activity. It is also possible that PTX is more 
readily released from PEG5K-FTS2(L) micelles due to the disintegration of the micellar system 
following the cleavage and release of FTS from PEG5K-FTS2(L) conjugate. More studies are 
needed to better understand the mechanism by which PTX/PEG5K-FTS2(L) mediated the 
cytotoxicity to tumor cells in vitro. 
In vivo, PTX formulated in both PEG5K-FTS2(L) and PEG5K-FTS2(S) micelles showed 
better antitumor activity than Taxol formulation although it is not statistically significant 
between Taxol and PTX/PEG5K-FTS2(S). This is likely due to a better stability of PEG5K-
FTS2(L) micellar formulation as demonstrated in release study (Figure 7).  Again, PTX/PEG5K-
FTS2(L) was more effective than PTX/PEG5K-FTS2(S) in antitumor activity in vivo. It remains to 
be determined if similar mechanisms are involved in the improved antitumor activity for 
PTX/PEG5K-FTS2(L) both in vitro and in vivo.  
In summary, a conjugate of PEG with two molecules of FTS forms small-sized micelles 
that effectively solubilize PTX. PTX formulated in this micellar system shows a PTX release 
kinetics that is significantly slower than that of Taxol. PEG5K-FTS2(L) conjugate well retains the 
biological activity of FTS and PTX formulated in PEG5K-FTS2(L) micelles is more active in 
cytotoxicity than free PTX in vitro. In vivo, PTX/PEG5K-FTS2(L) shows an antitumor activity 
that is more potent than that of Taxol or PTX/PEG5K-FTS2(S). PEG5K-FTS2(L) may represent a 
promising micellar system that could effectively deliver anticancer agents to tumors. 
Furthermore it may potentially synergize with co-delivered drugs in the overall antitumor 
activity.  
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3.0  PEG-FARNESYL THIOSALICYLIC ACID TELODENDRIMER MICELLES AS 
AN IMPROVED FORMULATION FOR TARGETED DELIVERY OF PACLITAXEL 
3.1 ABSTRACT 
We have recently designed and developed a dual-functional drug carrier that is based on 
poly(ethylene glycol) (PEG)-derivatized farnesylthiosalicylate (FTS, a nontoxic Ras antagonist). 
PEG5K-FTS2 readily form micelles (20-30 nm) and hydrophobic drugs such as paclitaxel (PTX) 
could be effectively loaded into these micelles. PTX formulated in PEG5K-FTS2 micelles showed 
an antitumor activity that was more efficacious than Taxol in a syngeneic mouse model of breast 
cancer (4T1.2). In order to further improve our PEG-FTS micellar system, four PEG-FTS 
conjugates were developed that vary in the molecular weight of PEG (PEG2K vs PEG5K) and the 
molar ratio of PEG/FTS (1/2 vs 1/4) in the conjugates. These conjugates were characterized 
including CMC, drug loading capacity, stability, and their efficacy in delivery of anticancer drug 
PTX to tumor cells in vitro and in vivo. Our data showed that the conjugates with four FTS 
molecules were more effective than the conjugates with two molecules of FTS and that FTS 
conjugates with PEG5K were more effective than the counterparts with PEG2K in forming stable 
mixed micelles. PTX formulated in PEG5K-FTS4 micelles was the most effective formulation in 
inhibiting the tumor growth in vivo. 
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3.2 BACKGROUND 
Paclitaxel (PTX) is one of the first-line chemotherapeutic agents used in the treatment of patients 
with breast, ovarian, non-small cell lung cancer and advanced forms of Kaposi’s sarcoma. The 
mechanism involves interfering with the normal breakdown of microtubules during cell division 
[92]. Successful application of PTX in the clinic has been limited by its poor water solubility and 
the systemic toxicity. Taxol is a Cremophor EL/ethanol formulation of PTX that has been used in 
the clinic. However, Cremophor EL can cause hypersensitivity reactions, neuropathy, and other 
serious side effects [93]. Thus there is a need to develop an alternative delivery system for PTX. 
Various macromolecular delivery systems such as liposomes, dendrimers, and nanoparticles are 
under investigation, among which polymeric micelles have gained considerable attention owing 
to their ease of preparation and very small sizes (10-100 nm) [94, 95]. Recent studies have 
substantiated that sub-100 nm micelle sizes are critical for a delivery system to achieve effective 
tumor targeting [29, 32, 96-98]. 
Our group has previously developed PEG-FTS as a dual-functional carrier for the 
delivery of poorly water soluble anticancer drugs [67]. This system was constructed by coupling 
two molecules of S-trans, trans-farnesylthiosalicylic acid (FTS) to polyethylene glycol (PEG, 
MW = 5000) through an ester linkage (PEG5K-FTS2). Different from most reported delivery 
systems that use “inert” excipients, our system employ a water-insoluble drug FTS as the 
hydrophobic region of the polymeric micelles. FTS is a nontoxic Ras antagonist [99]. It can 
inhibit both oncogenically activated Ras and growth factor receptor-mediated Ras activation, 
resulting in the inhibition of Ras-dependent tumor growth [55, 56]. A preliminary study showed 
that the antitumor activity of FTS was well retained following coupling to PEG5K. Furthermore, 
PEG5K-FTS2 readily formed small-sized micelles (20-30 nm) that are effective in loading and 
 37 
delivering PTX. The in vivo study demonstrated that the antitumor activity of the PTX-loaded 
PEG5K-FTS2 micelles was significantly higher than that of Taxol [67]. 
Recent studies have shown that the Vitamin E-based micellar system could be 
significantly improved via modulating the PEG motifs and the molar ratio of PEG/Vitamin E 
[100, 101]. In another study with PEG-embelin system, we have shown that a conjugate with two 
embelin molecules linked to PEG was significantly more effective than the conjugate with one 
embelin molecule coupled to PEG. This has prompted us to carry out a similar study with the 
PEG-FTS system [102]. Four PEG-FTS conjugates that vary in the molecular weight of PEG 
(PEG2K vs PEG5K) and the molar ratio of PEG/FTS (1/2 vs 1/4) have been developed. We 
demonstrated that PEG5K-FTS4 formed the most stable mixed micelles with PTX among the four 
PEG-FTS conjugates evaluated. Furthermore, PTX formulated in PEG5K-FTS4 micelles was the 
most effective formulation in inhibiting the tumor growth in vivo. 
 
3.3 EXPERIMENTAL PROCEDURES 
3.3.1 Materials 
Paclitaxel (98%) was purchased from AK Scientific Inc. (CA, USA). FTS was synthesized and 
purified following a published literature [103]. Dulbecco’s phosphate buffered saline (DPBS) 
was purchased from Lonza (MD, USA). Poly(ethylene glycol) methyl ether (MeO-PEG-OH, 
MW=2000, 5000 kDa), dimethyl sulfoxide (DMSO), succinate anhydride, diethanolamine, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), trypsin-EDTA solution, 
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Triton X-100, and Dulbecco’s Modified Eagle’s Medium (DMEM) were all purchased from 
Sigma-Aldrich (MO, USA). Fetal bovine serum (FBS) and penicillin-streptomycin solution were 
purchased from Invitrogen (NY, USA). N-hydroxysuccinimide (NHS) and 
dicyclohexylcarbodiimide (DCC) were purchased from Alfa Aesar (MA, USA). 4-
(dimethylamino) pyridine (DMAP) was purchased from Calbiochem-Novabiochem Corporation 
(CA, USA). All solvents used in this study were HPLC grade. 
3.3.2 Cell culture 
MCF-7 is a human breast carcinoma cell line. 4T1.2 is a mouse metastatic breast cancer cell line. 
HCT-116 is a human colon carcinoma cell line. All cell lines were cultured in DMEM containing 
5% FBS and 1% penicillin-streptomycin at 37 ℃ in a humidified 5% CO2 atmosphere. 
3.3.3 Synthesis of PEG2K-FTS2, PEG2K-FTS4, PEG5K-FTS2 and PEG5K-FTS4 
PEG5K-FTS4 was prepared via solution phase condensation reactions (Figure 13). We started to 
synthesize two hydroxyl group terminated PEG monomethyl ether (MeO-PEG5k-OH2) by 
following a published procedure [17]. Carboxyl terminated PEG monomethyl ether (MeO-
PEG5k-COOH2) was synthesized from MeO-PEG5k-(OH)2 by a facile chemical reaction with 
succinic anhydride and DMAP. To obtain four hydroxyl groups terminated PEG monomethyl 
ether (MeO-PEG5k-OH4), diethanolamine was coupled onto the carboxylic group of MeO-
PEG5k-COOH2 using NHS/DCC as coupling agent in chloroform overnight. The polymer was 
precipitated and washed by ice-cold diethyl ether and ethanol twice respectively, and 
concentrated under vacuum. MeO-PEG5k-OH4, FTS, DCC and DMAP were then dissolved in 
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chloroform and allowed to react overnight at room temperature. The solution was filtered and 
precipitated in ice-cold diethyl ether and ethanol twice respectively, and concentrated under 
vacuum. The powder was then dissolved in water and filtered through a filter with a pore size of 
0.22 μm. The final product was obtained by lyophilizing the filtrate. PEG2K-FTS4 was similarly 
synthesized as PEG5K-FTS4. PEG5K-FTS2 and PEG2K-FTS2 were synthesized following the 
literature [104]. 
 
 
 
Figure 13. Synthesis scheme of PEG5K-FTS4 conjugate 
3.3.4 Preparation of drug-loaded and drug-free micelles 
PTX (10 mM in chloroform) and four PEG-FTS conjugates (10 mM in chloroform) were mixed 
at various carrier/drug ratios. The organic solvent was removed by nitrogen flow to form a thin 
film of drug/carrier mixture. The film was dried under vacuum for 1 h to remove the remaining 
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solvent. DPBS was added to hydrate the thin film and the drug-loaded micelles were formed. 
Unincorporated PTX (precipitate) was removed by filtering through a syringe filter (pore size: 
0.22 μm). The drug-free micelles were similarly prepared as described above. 
3.3.5 Characterizations of drug-loaded and drug-free micelles 
The particle size and zeta potential of micelles were measured by a Zetasizer (DLS) (Zetasizer 
Nano ZS instrument, Malvern, Worcestershire, UK). The morphology and size distribution of 
drug-free or drug-loaded PEG2K-FTS2, PEG2K-FTS4, PEG5K-FTS2 and PEG5K-FTS4 micelles 
were observed using transmission electron microscopy (TEM). A copper grid with Formvar was 
used. The copper grid was immersed in a drop of sample solution and stained with 1% uranyl 
acetate. Imaging was performed at room temperature on JEOL JEM-1011.  
The critical micelle concentrations (CMC) of four PEG-FTS micelles were determined by 
using pyrene as a fluorescence probe [13]. Four PEG-FTS conjugates, PEG2K-FTS2, PEG2K-
FTS4, PEG5K-FTS2 and PEG5K-FTS4, were prepared in chloroform at 1.2 mg/mL, and various 
amounts were added to 9 separate vials. Then 10 μl of 1.8 × 10-4 M of pyrene in chloroform was 
added to each vial and the solution was mixed well. The organic solvent was removed by oil 
pump, and then 3 mL Milli-Q water was added to each vial.  The final pyrene concentration was 
6×10-7 M with the four PEG-FTS conjugate concentrations ranging from 0.0001 to 0.5 mg/mL. 
The vials were kept on a shaker for 24 h at 37℃ to reach equilibrium before fluorescence 
measurement. The fluorescence intensities of samples were measured at the excitation 
wavelength of 334 nm and emission wavelength of 390 nm by Synergy H1 Hybrid Multi-Mode 
Microplate Reader (Winooski, VT). The CMC is determined from the threshold concentration, 
where the sharp increase in pyrene fluorescence intensity is observed. 
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The PTX loading efficiency was quantified by high performance liquid chromatography 
(HPLC) (Alliance 2695-2998 system) as described previously [104]. Drug loading capacity 
(DLC) and drug loading efficiency (DLE) were calculated according to the following equation:  
DLC (%) = [weight of drug loaded/(weight of polymer + drug used)] ×100% 
DLE (%) = (weight of loaded drug/weight of input drug) ×100% 
3.3.6 In vitro PTX release study 
The in vitro PTX release kinetics for the four PEG-FTS micelles was determined by a dialysis 
method according to our published protocol [67]. Briefly, PTX loaded PEG-FTS micelles at a 
concentration of 0.5 mg PTX/mL were placed into a dialysis bag (MW cutoff 14000). The 
dialysis bag was incubated in 200 mL PBS containing 0.5% (w/v) Tween 80 with gentle shaking 
at 37 °C. The concentrations of PTX remaining in the dialysis bag at designated time points were 
measured by HPLC. 
3.3.7 Hemolytic effect of PEG-FTS micelles 
Hemolysis assay was performed using fresh blood collected through cardiac puncture from rats 
[105]. Red blood cells (RBCs) were collected by centrifugation and washed with PBS three 
times. Then RBCs were diluted in PBS to a final concentration of 2% w/v. One mL of diluted 
RBC suspension was mixed with different concentrations (0.2 and 1.0 mg/mL) of four PEG-FTS 
micelles and PEI, respectively, and then incubated at 37 ℃ in an incubator shaker for 4 h. The 
mixtures were centrifuged and supernatants were transferred into a 96-well plate. The release of 
hemoglobin was determined at 540 nm absorbance using a microplate reader. RBCs incubated 
 42 
with PBS and Triton X-100 (2%) were used as the negative and positive controls, respectively. 
The percentage of hemolysis of RBCs was calculated as (ODsample-ODnegative control)/(ODpositive 
control-ODnegative control) × 100%. 
3.3.8 In vitro cytotoxicity study 
The cytotoxicity of PTX formulated in PEG2K-FTS2, PEG2K-FTS4, PEG5K-FTS2 and PEG5K-FTS4 
micelles was assessed with several cancer cell lines and compared to free PTX in DMSO 
respectively. Briefly, 4T1.2 (1000 cells/well) cell lines were seeded in 96-well plates. After 24 h 
of incubation in DMEM with 5% FBS and 1% streptomycin-penicillin, the old medium was 
removed and the cells were incubated for 72 h in the presence of indicated concentrations of 
PTX (free or formulated in four PEG-FTS micelles). 100 µL of 3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) in DPBS (0.5 mg/mL) was added to each well and cells 
were further incubated for 2 h. MTT formazan was solubilized by DMSO. The absorbance in 
each well was measured by a microplate reader at a wavelength of 550 nm and a reference 
wavelength of 630 nm. Untreated groups were used as controls. Cell viability was calculated as 
[(ODtreat-ODblank)/(ODcontrol-ODblank) × 100%]. The cytotoxicity of PEG2K-FTS2, PEG2K-FTS4, 
PEG5K-FTS2 and PEG5K-FTS4 micelles alone was similarly tested in 4T1.2, MCF-7 and HCT-
116 cell line as described above.  
3.3.9 Western blotting 
Ras protein expression level in HCT-116 cells was evaluated by Western blotting following our 
published method [102]. Briefly, HCT-116 cells with 60-70% confluency in a 6-well plate were 
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treated with four PEG-FTS conjugates for 20 h at a FTS concentration of 40 µM. The antibodies 
used for Western blotting included those against Ras and β-actin. Bound antibodies were 
detected by chemiluminescence. 
 
3.3.10 Animals 
Female BALB/c mice, 4-6 weeks in age, were purchased from Charles River (Davis, CA). All 
animals were housed under pathogen-free conditions according to AAALAC guidelines. All 
animal-related experiments were performed in full compliance with institutional guidelines and 
approved by the Animal Use and Care Administrative Advisory Committee at the University of 
Pittsburgh. 
3.3.11 In vivo therapeutic study 
A syngeneic murine breast cancer model (4T1.2) was used to examine the therapeutic effect of 
different formulations of PTX. 2 x 105 4T1.2 cells in 200 μL PBS were inoculated s.c. at the 
right flank of female BALB/c mice. Treatments were started when tumors in the mice reached a 
tumor volume of ~ 50 mm3 and this day was designated as day 1. On day 1, these mice were 
randomly divided into six groups (n=5) and administered i.v. with PBS (control), Taxol (10 mg 
PTX/kg), PTX-loaded PEG2K-FTS2, PEG2K-FTS4, PEG5K-FTS2, and PEG5K-FTS4 micelles (10 mg 
PTX/kg), respectively on days 1, 3, 5, 8, 10 and 12. Tumor sizes were measured with digital 
caliper three times a week and calculated by the formula: (L×W2)/2, where L is the longest, and 
W is the shortest in tumor diameters (mm). To compare between groups, relative tumor volume 
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(RTV) was calculated at each measurement time point (where RTV equals to the tumor volume 
at a given time point divided by the tumor volume prior to first treatment). Mice were sacrificed 
before tumor reached 2000 mm3.  
To monitor the potential toxicity, the body weights of all mice from different groups were 
measured every three days. In addition, serum levels of transaminases (AST, ALT) in the mice 
with different treatments were investigated at the completion of the study. 
3.3.12 Statistical analysis 
In all statistical analysis, the significance level was set at a probability of P < 0.05. All results 
were reported as the mean ± standard deviation (SD), unless otherwise indicated. Statistical 
analysis was performed by Student’s t-test for two groups, and one-way ANOVA for multiple 
groups, followed by Newman-Keuls test with a P < 0.05.  
3.4 RESULTS   
3.4.1 Synthesis of four PEG-FTS conjugates 
PEG5K-FTS4 conjugate, containing four molecules of FTS coupled to one molecule of PEG5K via 
a labile ester linkage, was developed by solution phase condensation reactions. The synthetic 
scheme is presented in Figure 13. 1H NMR spectra of PEG5K-FTS4 conjugate are shown in 
Figure 14. The intense peak at 3.66 ppm was attributable to the methylene protons of PEG. 
Carbon chain signals and benzene ring signals of FTS were located at 1.5-2.2 ppm and 7-8 ppm, 
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respectively. MALDI-TOF suggested that four FTS were successfully attached to PEG5K (Figure 
15). We also synthesized PEG2K-FTS2, PEG2K-FTS4, and PEG5K-FTS2 conjugates, which were 
confirmed by 1H NMR spectra and MALDI-TOF mass spectra (Figures 14 & 15).  
 
Figure 14. 1H NMR spectra (400MHz) of PEG2K-FTS2 (A), PEG2K-FTS4 (B), PEG5K-FTS2 (C) 
and PEG5K-FTS4 (D) conjugates in CDCl3. 
 
 
 
Figure 15. MADLI-TOF of PEG2K-FTS2 (A), PEG2K-FTS4 (B), PEG5K-FTS2 (C) and PEG5K-
FTS4 (D) conjugates. 
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3.4.2 Size and size distribution of micelles 
The four PEG-FTS conjugates readily formed micelles in aqueous solution with the particle sizes 
of 20-30 nm (Table 2). Dynamic light scattering (DLS) measurements showed that PEG5K-FTS4 
micelles had hydrodynamic sizes around 27 nm at the concentration of 20 mg/mL (Figure 16A). 
TEM revealed spherical particles with uniform size distribution (Figure 16B). The size observed 
by TEM shows good agreement with that determined by DLS (Figures 17 & 18). PTX could be 
effectively loaded into PEG5K-FTS4 micelles. The spherical shape and size distribution were well 
retained when PTX was loaded into micelles at a drug concentration of 1 mg/mL and a 
carrier/drug ratio of 2.5/1 (m/m) (Figure 16C & D). Similar results were shown for the other 
three micelles (Figures 17 & 18).  
 
 
Figure 16. Particle size distribution and morphology of drug-free and PTX-loaded PEG5K-FTS4 
micelles.  
The size and size distribution of drug-free PEG5K-FTS4 micelles (A) and PTX-loaded PEG5K-
FTS4 micelles (C) were evaluated by DLS. The morphology of drug-free PEG5K-FTS4 micelles 
(B) and PTX-loaded PEG5K-FTS4 micelles (D) was examined by TEM. The PTX concentration 
was kept at 1 mg/mL. 
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Table 2. Size and CMC of four PEG-FTS conjugates 
Conjugates Sizea PDIb CMCc (µM) 
PEG2K-FTS2 25.75 0.09 1.22 
PEG2K-FTS4 26.12 0.15 1.43 
PEG5K-FTS2 17.61 0.13 0.34 
PEG5K-FTS4 26.80 0.12 0.29 
 
aMeasured by dynamic light scattering particle sizer. bPDI = polydispersity index. cCMC = 
critical micelle concentration. 
 
 
Figure 17. The size distribution of free PEG2K-FTS2 (A), PEG2K-FTS4 (C), PEG5K-FTS2 (E) 
micelles and PTX-loaded PEG2K-FTS2 (B), PEG2K-FTS4 (D), PEG5K-FTS2 (F) micelles in PBS 
measured by dynamic light scattering (DLS). 
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Figure 18. Transmission electron microscopy (TEM) of free PEG2K-FTS2 (A), PEG2K-FTS4 (C), 
PEG5K-FTS2 (E) micelles and PTX-loaded PEG2K-FTS2 (B), PEG2K-FTS4 (D), PEG5K-FTS2 (F) 
micelles.   
3.4.3 Critical micelle concentration (CMC)  
The CMC of PEG2K-FTS2, PEG2K-FTS4, PEG5K-FTS2 and PEG5K-FTS4 micelles were measured 
using pyrene as a fluorescence probe (Table 2). When the concentration of the PEG-FTS reached 
the CMC, the fluorescence intensity of pyrene would change dramatically due to the transfer of 
pyrene from polar micro-environment to non-polar surroundings caused by the formation of 
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micelles. The CMCs of PEG5K-FTS2 and PEG5K-FTS4 conjugates were determined to be 0.34 
μM and 0.29 µM, respectively, which were lower than those of PEG2K-FTS2 (1.22 µM) and 
PEG2K-FTS4 (1.43 µM) (Figure 19). The lower CMCs of PEG5K-FTS micelles may be attributed 
to the longer PEG hydrophilic chain and more effective stabilizing effect for the micelles. 
 
Figure 19. Critical micelle concentration (CMC) of PEG2K-FTS2 (A), PEG2K-FTS4 (B), PEG5K-
FTS2 (C) and PEG5K-FTS4 (D) micelles. 
3.4.4 Drug loading 
The PTX loading of PEG2K-FTS2, PEG2K-FTS4, PEG5K-FTS2 and PEG5K-FTS4 micelles with 
different carrier to drug molar ratios was determined by HPLC (Table 3). The sizes of these PTX 
loaded PEG-FTS micelles were also evaluated under corresponding conditions. PEG5K-FTS4 
micelles could effectively solubilize PTX in aqueous solution at a molar ratio as low as 1:1 
(m/m) with particle size around 50 nm (Table 3). However, these PTX-loaded PEG5K-FTS4 
micelles were only stable for 2.5 h. With an increase in carrier/drug ratio to 2.5/1, they formed 
mixed micelles with PTX that were stable for about one day. For the other three micelles, a 
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minimal carrier/drug ratio of 2.5/1 was required to solubilize PTX. Overall, the conjugates with 
four molecules of FTS worked better than the conjugates with two molecules of FTS and PEG5K 
conjugates were more effective than the PEG2K counterparts in forming stable drug loaded 
micelles. The four conjugates were ranked as PEG5K-FTS4 > PEG2K-FTS4 > PEG5K-FTS2 > 
PEG2K- FTS2 with respect to their efficiency in forming stable mixed micelles with PTX.  
Table 3. Serum levels of transaminases in mice of different treatment groups 
Groups ALT ( U/L) AST ( U/L) 
PBS 37.3 ± 1.0 94.3 ± 20.4 
Taxol (10 mg/kg) 22.2 ± 4.1 97.6 ± 1.4 
PEG2K-FTS2/PTX (10 mg/kg) 23.2 ± 1.7 102.6 ± 15.9 
PEG2K-FTS4/PTX (10 mg/kg) 26.4 ± 1.0 94.3 ± 36.4 
PEG5K-FTS2/PTX (10 mg/kg) 22.2 ± 0.7 86.3 ± 11.5 
PEG5K-FTS4/PTX (10 mg/kg) 24.0 ± 2.8 130.3 ± 28.8 
ALT  = alanine aminotransferase 
AST  = aspartate aminotransferase 
3.4.5 In vitro PTX release study 
 
Figure 20. Cumulative PTX release profile from four PTX-loaded PEG-FTS micelles.  
PBS containing 0.5% (w/v) Tween 80 was used as the release medium. PTX concentration was 
fixed at 0.5 mg PTX/mL. Values reported are the means ± SD for triplicate samples.  
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The profile of PTX release from the four PEG-FTS micelles was examined by a dialysis method. 
As shown in Figure 20, PEG5K-FTS4/PTX mixed micelles showed relatively slower kinetics of 
PTX release compared to other PTX-loaded PEG-FTS micelles. 
3.4.6 Hemolytic effect of PEG-FTS micelles 
As a delivery system for intravenous application, the potential detrimental interaction of PEG-
FTS-based micellar system with blood components should be minimized. Figure 21 shows the 
hemolytic activities of drug-free PEG2K-FTS2, PEG2K-FTS4, PEG5K-FTS2 and PEG5K-FTS4 
micelles. Polyethylenimine (PEI), a cationic polymer known to have significant hemolytic effect 
[86], was included as a positive control. PEI induced hemolysis in a concentration-dependent 
manner. In contrast, all of the four drug-free PEG-FTS micelles displayed only negligible levels 
of hemolytic activities, suggesting that PEG-FTS micelles are mild surfactants suitable for in 
vivo delivery of hydrophobic anticancer drugs. 
 
Figure 21. In vitro hemolysis assay of four PEG-FTS micelles compared with PEI.  
Rat RBCs were treated with the 4 different PEG-FTS micelles or PET at 0.2 and 1 mg/mL, 
respectively. The lysis of RBCs was determined by measuring the release of hemoglobin 
spectrophotometrically (λ = 540 nm). RBCs incubated with PBS and Triton X-100 (2%) were 
used as the negative and positive controls. Values reported are the means ± SD for triplicate 
samples. 
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3.4.7 In vitro cytotoxicity 
Figure 22A shows the cytotoxicity of 4 carriers alone in MCF-7 cells. The FTS2 conjugates 
(PEG2K-FTS2 and PEG5K-FTS2) were more effective than FTS4 conjugates (PEG2K- FTS4 and 
PEG5K-FTS4) in inhibiting the tumor cell proliferation. Similar results were found when the four 
conjugates were examined in HCT-116 (Figure 22B) and 4T1.2 cells (Figure 22C).  
 
Figure 22. Cytotoxicity of four drug-free PEG-FTS micelles in MCF-7 human breast carcinoma 
cell line (A), HCT-116 human colon carcinoma cell line (B) and 4T1.2 mouse breast cancer cell 
line (C).  
Cells were treated with different micelles for 72 h and cytotoxicity was determined by MTT 
assay. Values reported are the means ± SD for triplicate samples. 
3.4.8 Western blotting 
Figure 23 shows the protein expression level of total Ras 20 h following treatment of HCT-116 
cells with the four different conjugates at a FTS concentration of 40 µM. Downregulation of Ras 
protein expression was seen in all treatment groups. However, the conjugates with two FTS 
molecules were more active than the counterparts with four FTS molecules in reducing the 
protein expression levels of Ras in HCT-116 cells. 
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Figure 23. Effects of PEG-FTS micelles on total Ras protein expression in HCT-116 cells.  
HCT-116 cells were treated with four different PEG-FTS micelles for 20 h (at a FTS 
concentration of 40 µM). The protein expression level of total Ras was examined by Western 
blotting. 
3.4.9 In vitro cytotoxicity of PTX-loaded micelles 
Figure 24 shows the cytotoxicity of free PTX (in DMSO) and PTX formulated in PEG2K-FTS2, 
PEG2K-FTS4, PEG5K-FTS2 and PEG5K-FTS4 micelles in 4T1.2 cell line. Free PTX inhibited the 
cell growth in a dose-dependent manner. Delivery of PTX via the four different PEG-FTS 
micelles led to varied levels of improvement. Nonetheless, PTX-loaded PEG5K-FTS4 micelles 
were more potent than PTX formulated in the other micellar formulations (PEG2K-FTS2, PEG2K-
FTS4 and PEG5K-FTS2) in inhibiting the tumor cell growth. The IC50 of free PTX and the four 
micellar formulations of PTX are summarized in Table 4. 
 
Table 4. IC50 of PTX-loaded PEG-FTS micelles compared to free PTX in 4T1.2 mouse breast 
cancer cell line. 
IC50 (ng/mL) 
PTX PEG2K-FTS2/PTX PEG2K-FTS4/PTX PEG5K-FTS2/PTX PEG5K-FTS4/PTX 
202.0  72.8  181.8  59.3  33.2  
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Figure 24. Cytotoxicity of PTX-loaded PEG-FTS micelles in 4T1.2 mouse breast cancer cell 
line.  
Cells were treated with free PTX or different micellar formulations of PTX for 72 h and 
cytotoxicity was determined by MTT assay. PTX-loaded PEG5K-FTS4 micelles showed an 
improvement in cell growth inhibition compared with other formulations. *P<0.05 (PTX/PEG5K-
FTS4 vs PTX), 
#P<0.05 (PTX/PEG5K-FTS4 vs PTX/PEG5K-FTS2 or PTX/PEG2K-FTS4), 
&P<0.05 
(PTX/PEG5K-FTS4 vs PTX/PEG2K-FTS2, PTX/PEG5K-FTS2 or PTX/PEG2K-FTS4). Values 
reported are the means ± SD for triplicate samples. 
3.4.10 In vivo therapeutic study 
The in vivo therapeutic effectiveness of PTX formulated in PEG2K-FTS2, PEG2K-FTS4, PEG5K-
FTS2, and PEG5K-FTS4 micelles was evaluated, respectively, in a syngeneic murine breast cancer 
model (4T1.2), and compared to Taxol. As shown in Figure 25A, PTX-loaded PEG2K-FTS2 
micelles exhibited a similar tumor growth inhibitory effect compared to Taxol treatment group. 
In contrast, PTX formulated in PEG5K-FTS2 and PEG5K-FTS4 micelles demonstrated a 
significantly enhanced antitumor activity compared to Taxol (P < 0.01). Furthermore, PTX 
formulated in PEG5K-FTS4 showed a trend of improvement in antitumor activity compared with 
PTX formulated in PEG5K-FTS2 (P = 0.09). No significant changes in body weight were noticed 
in all treatment groups compared to PBS control group (Figure 25B). In addition, serum levels 
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of transaminases in the mice with different treatments were comparable to those in PBS control 
group (Table 5). 
 
 
Figure 25. Enhanced anti-tumor efficacy of PTX loaded in PEG5K-FTS4 micelles.  
BABL/c mice were inoculated s.c. with 4T1.2 cells (2 × 105 cells/mouse). Six days later, mice 
received various treatments twice a week and tumor growth was monitored and plotted as 
relative tumor volume (A). Significant improvement in antitumor activity was found for the 
PTX-loaded PEG5K-FTS4 group compared with the Taxol group (**P<0.01; N=5) and the group 
of PTX-loaded PEG2K-FTS2 (*P<0.05; N=5). Changes in body weights of mice in different 
treatment groups were also monitored (B). 
 
Table 5. Serum levels of transaminases in mice of different treatment groups 
Groups ALTa ( U/L) ASTb ( U/L) 
PBS 37.3 ± 1.0 94.3 ± 20.4 
Taxol (10 mg/kg) 22.2 ± 4.1 97.6 ± 1.4 
PEG2K-FTS2/PTX (10 mg/kg) 23.2 ± 1.7 102.6 ± 15.9 
PEG2K-FTS4/PTX (10 mg/kg) 26.4 ± 1.0 94.3 ± 36.4 
PEG5K-FTS2/PTX (10 mg/kg) 22.2 ± 0.7 86.3 ± 11.5 
PEG5K-FTS4/PTX (10 mg/kg) 24.0 ± 2.8 130.3 ± 28.8 
ALTa  = alanine aminotransferase 
ASTb  = aspartate aminotransferase 
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3.5 DISCUSSION 
We have systematically compared the physicochemical property and the in vitro and in vivo PTX 
delivery efficiency of four PEG-FTS conjugates that vary in the length of PEG motif (PEG2K vs 
PEG5K) and the molar ratio of PEG/FTS (1/2 vs 1/4). All of the four PEG-FTS micelles 
possessed very small sizes of 20-30 nm. After drug loading, micelles retained small size of 20-60 
nm. Doxil (doxorubicin HCl liposome) and Abraxane (albumin-bound paclitaxel) are two FDA-
approved formulations. The particle sizes of Doxil and Abraxane are ~150 and 130 nm, 
respectively. Their relatively large sizes may limit the diffusion in the tumor, and thus limit their 
therapeutic effectiveness [106]. It has been reported that nanoparticles need to be smaller than 
100 nm in order to circumvent macrophage clearance in the lungs [15] and that particles of 
further reduced size (≤ 64 nm) are needed for effective penetration through neovasculatures to 
reach tumor cells [17, 32]. The small sizes of our PEG-FTS micelles shall ensure efficient 
passive targeting to the solid tumors.  
In addition to size, drug loading capacity and formulation stability are two other 
important features for an effective micellar system. Our data showed that the PEG-FTS 
conjugates with four FTS molecules were significantly more effective than the conjugates with 
two molecules of FTS in forming stable drug-loaded micelles. Previous studies have shown that 
increasing the ratio of hydrophobic/hydrophilic blocks is associated with increased drug loading 
capacity and enhanced formulation stability [32]. The improved performance of PEG-FTS 
conjugates with an increased number of core forming units may be attributed to a similar 
mechanism. FTS, as a hydrophobic core of micelles, has a lipid chain and benzene ring structure. 
The lipid chain of FTS contributes to the loading of hydrophobic drug through hydrophobic 
interaction. At the same time, the benzene ring of FTS is capable of forming π-π interaction with 
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drug carrying aromatic ring structure. In PEG-FTS micellar system, π-π stacking and 
hydrophobic interaction are likely to work cooperatively to promote both drug/carrier and 
carrier/carrier interactions. Such interactions are also expected to be further enhanced with an 
increase in the number of FTS molecules in PEG-FTS conjugates. 
PEG is widely used as a polymeric steric stabilizer. A prominent advantage of PEG 
modification is to impart the in vivo longevity to drug carriers. Torchilin’s group [20] has 
reported that the PEG/core ratio affected the performance of the micelles. Furthermore, the 
length of PEG also acted on the CMC, which in turn influenced the performance of the micelles, 
particularly in vivo [8, 102]. Our data showed that PEG5K-conjugates had a lower CMC and were 
more effective than PEG2K-conjugates in forming stable micelles with PTX.  
One unique feature for PEG-FTS micellar delivery system is its intrinsic antitumor 
activity. The four different PEG-FTS conjugates showed varied levels of antitumor activity by 
themselves in three cancer cell lines. The conjugates with two FTS molecules showed higher 
levels of cytotoxicity compared to the counterparts with four FTS molecules. The higher levels 
of cytotoxicity for the conjugates with two FTS molecules are unlikely due to a more active 
surface activity of the double chain conjugates as all of the four conjugates showed minimal 
hemolytic activity (Figure 21). It is likely that active FTS is more readily cleaved from the 
conjugates with two FTS than the ones with four FTS molecules due to less steric hindrance to 
intracellular esterases. We also compared the in vitro cytotoxicity of the four PTX-loaded PEG-
FTS micelles (Figure 24). PTX-loaded PEG5K-FTS4 micelles showed better cytotoxicity than 
free PTX and PTX formulated in other three micelles in 4T1.2 cells. This is likely due to a more 
efficient intracellular delivery of PTX via PEG5K-FTS4 micelles because PEG5K-FTS4 formed the 
most stable micelles with PTX among the four micellar systems tested.  
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In vivo therapy study clearly showed a significantly higher level of antitumor activity for 
PTX formulated in PEG5K-FTS4 micelles compared to either Taxol or PTX formulated in PEG2K-
FTS2 (Figure 25A). This is likely due to the significantly improved stability for PEG5K-FTS4 
micelles, which contributes to more effective delivery of PTX to tumor tissue in vivo. 
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4.0  TARGETED DELIVERY OF ANTICANCER AGENTS VIA A DUAL FUNCTION 
NANOCARRIER WITH AN INTERFACIAL DRUG-INTERACTIVE MOTIF 
4.1 ABSTRACT 
We have developed a dual-function drug carrier, polyethylene glycol (PEG)-derivatized 
farnesylthiosalicylate (FTS). Here we report that incorporation of a drug-interactive motif (Fmoc) 
into PEG5k-FTS2 led to further improvement in both drug loading capacity and formulation 
stability. Doxorubicin (DOX) formulated in PEG5k−Fmoc−FTS2 showed sustained release 
kinetics slower than those of DOX loaded in PEG5k-FTS2. The maximum tolerated dose of 
DOX- or paclitaxel (PTX)-loaded PEG5k-Fmoc-FTS2 was significantly higher than that of the 
free drug. Pharmacokinetics and biodistribution studies showed that DOX/PEG5k-Fmoc-FTS2 
mixed micelles were able to retain DOX in the bloodstream for a significant amount of time and 
efficiently deliver the drug to tumor sites. More importantly, drug (DOX or PTX)-loaded PEG5k-
Fmoc-FTS2 led to superior antitumor activity over other treatments including drugs formulated in 
PEG5k-FTS2 in breast cancer and prostate cancer models. Our improved dual function carrier 
with a built-in drug-interactive motif represents a simple and effective system for targeted 
delivery of anticancer agents. 
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4.2 BACKGROUD 
Formulations represent an important strategy to improve the therapeutic index of anticancer 
agents via improving their solubility, bioavailability, and pharmacokinetic and biodistribution 
profiles [97, 107]. Taxol® is a FDA-approved clinical formulation of paclitaxel (PTX) in which 
Cremophor EL/ethanol (1:1, v/v) mixture is used to solubilize PTX. However, Taxol® can cause 
hyperactivity reactions, neuropathy, and other serious side effects [93]. PEGylated liposomal 
doxorubicin (DOX) (Doxil®) is the first nanoformulation of DOX approved by the FDA. 
Although Doxil® has demonstrated decreased cardiotoxicity, it shows limited improvement over 
free DOX in therapeutic efficacy. In addition, Doxil is associated with other side effects such as 
hand-foot syndrome [108]. Over the last 2-3 decades, micelles with a nanoscopic supramolecular 
core-shell structure have gained increasing attention [5, 109] due to their easy preparation, small 
sizes, and their ability to improve the pharmacokinetics and efficacy of anticancer drugs [13, 18, 
40, 110, 111]. However, most delivery systems involve the use of “inert” materials that do not 
possess any favourable biological activity. One interesting approach is the development of dual 
function carriers that have both a delivery function and an antitumor activity [65, 67, 97, 100, 
102, 112, 113]. 
We have recently reported a new self-assembling nanomicellar system that is based on 
pegylated S-trans, trans-farnesylthiosalicylic acid (FTS) [67]. FTS, a synthetic farnesylcysteine 
mimetic, is a potent and especially nontoxic Ras antagonist [82, 114]. Constitutively active Ras 
caused by mutation in the Ras family of proto-oncogenes is present in one-third of human 
cancers [53, 115]. FTS can inhibit Ras-dependent tumor growth with no adverse toxicity [57]. 
One major mechanism involves affecting membrane interaction of Ras by competing with Ras 
for binding to Ras-escort proteins, and thereby inhibiting its signaling [55]. In addition to its 
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antitumor activity in mice and humans, FTS also exhibits anti-inflammatory activity [64, 99]. 
However, FTS has poor water solubility and limited oral bioavailability [66]. PEGylation was 
initially designed to improve its solubility. Interestingly, the PEG5k-FTS2 conjugate self-
assembled to form small-sized micelles (20-30 nm) that were effective in solubilizing other 
hydrophobic drugs such as PTX. PEG5k-FTS2 differs from most drug carriers in that it shows an 
antitumor activity that is comparable to that of free FTS [67]. Additionally, PTX formulated in 
PEG5k-FTS2 micelles demonstrated a synergistic antitumor activity that was significantly higher 
than that of Taxol [67].  
Most reported micellar systems including PEG5k-FTS2 are designed to load drugs through 
hydrophobic interactions. While working well for highly hydrophobic drugs, they only have 
limited effectiveness in formulating drugs that are either moderately hydrophobic or hydrophilic. 
The carrier/drug incompatibility will result in not only low drug loading capacity but also limited 
stability of the drug-loaded micelles [116]. Park’s group has shown that inclusion of less 
hydrophobic and hydrogen bond-forming “hydrotropic motifs” into the hydrophobic domain of 
polymeric micelles significantly improved both drug loading capacity and the colloidal stability 
of drug-loaded micelles [68, 116, 117]. However, this concept has not been demonstrated in 
lipidic systems. We hypothesized that incorporation of a drug-interactive motif into a surfactant 
at the interfacial region will provide an additional carrier/drug interaction mechanism, which 
could enhance both drug-loading capacity and formulation stability [69, 110]. Among several 
motifs screened, the 9-Fluorenylmethoxycarbony (Fmoc) moiety, a functional group that is 
routinely used for amino acid protection, was demonstrated to be the most potent drug-
interactive group [69]. We demonstrated that incorporation of Fmoc motifs into a PEG-
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lipopeptide conjugate led to a significant improvement in loading of a number of therapeutic 
agents of diverse structures [70, 118].  
Considering the significance of Fmoc as a novel “formulation chemophor” or a structural 
unit capable of interacting with many pharmaceutical agents, we hypothesized that incorporation 
of Fmoc will further improve the performance of our PEG5k-FTS2 delivery system. We report in 
this study the development and characterization of a new micellar carrier composed of an FTS-
based hydrophobic domain, a PEG hydrophilic segment and a drug-interactive Fmoc motif 
(PEG5k-Fmoc-FTS2). Our data showed that inclusion of an Fmoc motif into PEG5k-FTS2 led to a 
significant improvement in drug loading capacity for both PTX and DOX. More importantly, 
delivery of PTX or DOX via PEG5k-Fmoc-FTS2 led to superior antitumor activity over other 
treatments including drugs formulated in PEG5k-FTS2 micelles in breast cancer and prostate 
cancer models. 
4.3 EXPERIMENTAL PROCEDURE 
4.3.1 Materials  
Paclitaxel (98%) was purchased from AK Scientific Inc. (CA, USA). Doxorubicin (>99%) was 
purchased from LC Laboratories (MA, USA). 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindodicarbocyanine perchlorate, D-307 (DiD) were purchased from Invitrogen (NY, 
USA). N-hydroxysuccinimide (NHS) and dicyclohexylcarbodiimide (DCC) were purchased from 
Alfa Aesar (MA, USA). 4-(dimethylamino) pyridine (DMAP) was purchased from Calbiochem-
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Novabiochem Corporation (CA, USA). FTS was synthesized and purified following a published 
literature [103]. 
4.3.2 Synthesis of PEG5K-Fmoc-FTS2 conjugate 
PEG5K-Fmoc-FTS2 was synthesized via solution condensation reactions from poly(ethylene 
glycol) methyl ether (mPEG-OH, Mw=5000 Da) (mPEG5K-OH) (Figure 26). MPEG5K-OH was 
reacted with succinate anhydride (5 eq.) in CH2Cl2 overnight using DMAP (5 eq.) as a catalyst. 
The PEG derivative was precipitated with 10 volume of cold ether and washed with ether twice. 
Excess DMAP was removed by additional washes with cold ethanol (Yield = 91%). The 
carboxy-terminated mPEG (mPEG5K-COOH) was then reacted with 
tris(hydroxymethyl)aminomethane (Tris) in the presence of NHS (3 eq.) and DCC (3 eq.) in 
CH2Cl2 for one day, followed by a similar purification step as described above (Yield = 92%). 
The two hydroxyl groups in the PEG-derivatized Tris were blocked by forming acetonide using 
p-Toluenesulfonic acid (TsOH) as a catalyst in acetone (Quantitative). Then, Fmoc group was 
coupled to the remaining OH of Tris via reaction with 9-fluorenylmethoxycarbonyl chloride 
(Fmoc-Cl) (2 eq.) and triethylamine (3 eq.) in CH2Cl2 overnight. PEGylated molecules were 
similarly purified as described above and acetonide group was removed by treatment with 1% 
TsOH in CH2Cl2 (Yield = 50%, 2 steps). Finally, FTS (4 eq.) was coupled onto the PEGylated 
molecules with DCC (4 eq.) and DMAP (0.4 eq.) as the coupling reagents. The reaction mixture 
was filtered and precipitated with ether and ethanol twice, and concentrated under vacuum (Yield 
= 85%). The powder was then dissolved in water and filtered through a filter with a pore size of 
0.2 μm. The final product was obtained by lyophilizing the filtrate. PEG5K-FTS2 was synthesized 
following our reported method [67]. 
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Figure 26. Synthesis scheme of PEG5K-Fmoc-FTS2 conjugate 
4.3.3 Preparation and characterization of PTX- and DOX-loaded micelles 
PTX (10 mM in chloroform) and PEG5K-Fmoc-FTS2 conjugate (10 mM in chloroform) were 
mixed with various carrier/drug ratios. After removing chloroform, a thin film of drug/carrier 
mixture was formed. PTX-loaded micelles were formed by adding DPBS to hydrate the thin film 
followed by gentle votexing. To load DOX into PEG5K-Fmoc-FTS2 micelle, DOX∙HCl was first 
treated with triethylamine (3 eq.) in a mixture of chloroform (CHCl3)/methanol (MeOH) (1:1, 
v/v) to remove HCl from DOX∙HCl. DOX-loaded PEG5K-Fmoc-FTS2 micelles were then 
similarly prepared as described above. The PTX loading efficiency was quantified by high 
performance liquid chromatography (HPLC) as described before [67]. The DOX loading 
efficiency was examined by Waters Alliance 2695 Separations Module combined with Waters 
2475 Fluorescence Detector (Excitation: 490 nm; Emission: 590 nm; Gain: 3; Sensitivity 
(FUFS): 10000). Hibar 250-4 LiChrosorb RP-8 (5 micron) column (Sorbent Lot no. L59040432) 
was used and the mobile phase consisted of acetonitrile/water (52.5:47.5, v/v) with 2.5 mM 
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CH3COONH4 and 0.05% (v/v) CH3COOH. The flow rate of mobile phase was 1 mL/min and 
running time was 12 mins. Drug loading capacity (DLC) and drug loading efficiency (DLE) 
were calculated from the following equations:  
    DLC (%) = [weight of drug loaded/(weight of polymer + drug used)] ×100% 
    DLE (%) = (weight of loaded drug/weight of input drug) ×100% 
The mean diameter, morphology and size distribution of PEG5K-Fmoc-FTS2 micelles 
were assessed by dynamic light scattering (DLS) and transmission electron microscopy (TEM). 
The critical micelle concentration (CMC) of PEG5K-Fmoc-FTS2 micelles was determined using 
pyrene as a fluorescence probe [119]. The in vitro kinetics of DOX release from PEG5K-Fmoc-
FTS2 micelles was examined by a dialysis method [120]. The hemolytic effect of PEG5K-Fmoc-
FTS2 micelles was examined as described [102]. 
4.3.4 Cell culture and animals  
4T1.2 (mouse metastatic breast cancer cell line), MCF-7 (human breast carcinoma cell line), and 
A549 (human lung adenocarcinoma epithelial cell line) were obtained from ATCC (VA, USA). 
HCT116 (human colon carcinoma cell line) was kindly provided by Dr. Lin Zhang (University 
of Pittsburgh Cancer Institute). All cell lines were cultured in DMEM containing 5% FBS and 
1% penicillin-streptomycin at 37 ℃ in a humidified 5 % CO2 atmosphere. Female BALB/c mice, 
4-6 weeks in age, and CD-1 mice, 4-6 weeks in age, were purchased from Charles River (Davis, 
CA). Male nude mice, 6-8 weeks in age, were purchased from Harlan (Livermore, CA). All 
animals were housed under pathogen-free conditions according to AAALAC guidelines. All 
animal-related experiments were performed in full compliance with institutional guidelines and 
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approved by the Animal Use and Care Administrative Advisory Committee at the University of 
Pittsburgh.  
4.3.5 In vitro cytotoxicity study 
The cytotoxicity of drugs (PTX and DOX) formulated in PEG5K-Fmoc-FTS2 micelles was 
assessed with several cancer cell lines and compared to Taxol and free DOX, respectively, by 
MTT assay [67]. The cytotoxicity of free PEG5K-FTS2, PEG5K-Fmoc-FTS2 and FTS was also 
examined.  
4.3.6 Maximum tolerated dose (MTD) studies 
Groups of 4 female CD-1 mice were administered intravenously with free DOX (5, 10, 15, 20 
mg DOX/kg), DOX-loaded PEG5K-Fmoc-FTS2 micelles (5, 10, 15, 20, 25, 30 mg DOX/kg), 
Taxol (15, 20, 25 mg PTX/kg), or PTX-loaded PEG5K-Fmoc-FTS2 micelles (50, 75, 100, 120, 
140 mg PTX/kg), respectively. Changes in body weight and mouse survival were monitored 
daily for two weeks. The MTD was defined as the maximal dose that causes neither greater than 
15% of body weight loss nor mouse mortality within two weeks after administration [102]. 
4.3.7 NIRF optical imaging 
Nude mice bearing bilateral s.c. PC-3 xenografts were i.v. injected with 200 μL of DiD-loaded 
PEG5K-Fmoc-FTS2 at a concentration of 0.4 mg/mL. At indicated times (0.5 h, 6 h, 24 h, 48 h, 72 
h and 96 h), the mice were scanned using a Carestream Molecular Imaging System, In vivo 
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Multispectral FX PRO, with the excitation at 630 nm and the emission at 700 nm using a 30 s 
exposure time. The mice were anesthetized by isoflurane inhalation before each imaging. After 
96 h, the mice were euthanized by CO2 overdose. The tumor and major organs were excised for 
ex vivo imaging. 
4.3.8 Plasma pharmacokinetics and tissue distribution 
DOX∙HCl and DOX-loaded PEG5K-Fmoc-FTS2 micelles were injected into female BALB/c mice 
via tail vein at a dose of 5 mg DOX/kg. The blood samples were collected in heparinized tubes at 
different time points (3 min, 8 min, 15min, 30 min, 1 h, 2 h, 4 h, 8 h, and 12 h) post-injection. 
The blood was centrifuged (2500 rpm, 10 min) and plasma was collected for the analysis. DOX 
in plasma was extracted by extraction buffer (10% Triton X-100, deionized water, and 
isopropanol at a volumetric ratio of 1:2:15) [110]. DOX was examined by HPLC using 
fluorescence detection. Non-compartmental pharmacokinetic analysis was done by WinNonlin. 
For tissue biodistribution study, DOX∙HCl and DOX-loaded PEG5K-Fmoc-FTS2 were injected 
into female BALB/c mice bearing 4T1.2 breast tumor at a dose of 5 mg DOX/kg, respectively. 
At day 1 post-injection, tumor tissues and major organs were collected from the mice. The 
tissues were weighed and homogenized using Homogenizer PowerGen 500 (Fisher Scientific). 
The tissue solutions were mixed with the extraction buffer and DOX was extracted overnight at -
20 °C. The solutions were centrifuged (2500 rpm, 10 min) and the supernatant was used for 
HPLC measurement. The concentrations of DOX in tissues were determined based on the 
standard curve of DOX in blood. 
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4.3.9 In vivo therapeutic study 
Two tumor models (a syngeneic murine breast cancer model (4T1.2) and a human prostate 
cancer (PC-3) xenograft model) were used to assess the therapeutic activity of PTX or DOX 
formulated in PEG5K-Fmoc-FTS2 micelles. The breast cancer model was established by 
inoculation of 4T1.2 cells (1 x 105) in 200 μL PBS at the right flank of female BALB/c mice. 
Treatments were started when tumors achieved a volume of ~50 mm3 and this day was 
designated as day 1. Then tumor-bearing mice were randomly divided into six groups (n=5) and 
administered i.v. with PBS (control), PEG5K-Fmoc-FTS2 micelles, Taxol (10 mg PTX/kg), PTX-
loaded PEG5K-Fmoc-FTS2 micelles (10, 20 mg PTX/kg), and PTX-loaded PEG5K-FTS2 (10 mg 
PTX/kg), respectively on days 1, 3, 5, 8, 11 and 14. Free PEG5K-Fmoc-FTS2 micelles were given 
at the equivalent dosage of the carrier in the group of PTX-loaded PEG5K-Fmoc-FTS2 micelles 
(10 mg PTX/kg). The therapeutic effect of DOX-loaded PEG5K-Fmoc-FTS2 micelles (5, 10 mg 
DOX/kg) was similarly evaluated in 4T1.2 tumor model. Controls include PBS, PEG5K-Fmoc-
FTS2 micelles, DOX∙HCl (5 mg DOX/kg), liposomal DOX (5 mg DOX/kg), and DOX-loaded 
PEG5K-FTS2 (5 mg DOX/kg). Tumor sizes were measured with digital caliper three times per 
week and calculated as V = (L×W2)/2, L = the longest diameter, W = the shortest diameter (mm). 
Each group was compared by relative tumor volume (RTV) (where RTV equals to the tumor 
volume divided by the initial tumor volume before treatment). Mice were sacrificed when the 
tumors developed ulceration or reached 2000 mm3. The body weights of all mice from different 
groups were monitored every three days. The antitumor activity of PTX-loaded PEG5K-Fmoc-
FTS2 micelles was further evaluated in a human prostate cancer xenograft model, PC-3. 
Different groups were similarly treated as described above on days 1, 3, 6, 9 and 12. Tumor size 
and body weight were monitored as described above.  
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4.3.10 Statistical analysis  
Data are presented as mean ± standard deviation (SD). Statistical analysis was performed by 
Student’s t-test for comparison of two groups, and comparisons for multiple groups were made 
with one-way analysis of variance (ANOVA), followed by Newman-Keuls test if the overall P < 
0.05. In all statistical analysis, the threshold of significance was defined as P < 0.05.  
4.4 RESULTS AND DISCUSSION 
4.4.1 Preparation and characterization of drug-loaded PEG5K-Fmoc-FTS2 micelles 
PEG5K-Fmoc-FTS2 conjugate, containing one Fmoc motif and two molecules of FTS coupled to 
one molecule of PEG via a labile ester linkage, was synthesized via solution condensation 
reactions (Figure 26 and 27). 1H NMR spectrum of PEG5K-Fmoc-FTS2 conjugate is shown in 
Figure 28, with signals at 3.63 ppm and 7-8 ppm attributable to the methylene protons of PEG 
and benzene ring protons of Fmoc motif, respectively. Carbon chain and benzene ring signals of 
FTS were located at 1.5-2.2 and 7-8 ppm, respectively. The molecular weight of the PEG5K-
Fmoc-FTS2 conjugate measured by MALDI-TOF Mass Spectra is close to the theoretical value 
(6105) (Figure 29), indicating the successful synthesis of PEG5K-Fmoc-FTS2 conjugate. 
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Figure 27. Chemical structure of PEG5K-Fmoc-FTS2 and the postulated model of carrier/drug 
interaction. 
 
 
Figure 28. 1HNMR spectra (400MHz) of PEG5K-Fmoc-FTS2 conjugate in CDCl3. 
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Figure 29. MADLI-TOF of PEG5K-Fmoc-FTS2 conjugate 
 
Similar to PEG5K-FTS2 micellar system, the PEG5K-Fmoc-FTS2 conjugate readily formed 
micelles in aqueous solution (Figure 30). DLS measurements showed that PEG5K-Fmoc-FTS2 
micelles had hydrodynamic sizes around 20 nm at the concentration of 20 mg/mL (Figure 30A). 
TEM showed spherical particles with a uniform size distribution (Figure 30B). PEG5K-Fmoc-
FTS2 conjugate forms small-sized micelles that were highly effective in solubilizing various 
anticancer drugs such as PTX, DOX (Tables 6 and 7), and many others (data not shown). It has 
been demonstrated that the size of the particles needs to be within sub-100 nm range for them to 
efficiently reach the poorly vascularized tumors [32]. Such small sizes are also critical to enable 
the particles effective in deep penetration into the tumor tissues, especially the tumors with a 
tough tangle of collagen such as pancreatic and some breast cancers [98]. 
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Figure 30. The size distribution and morphology of free drug PEG5K-Fmoc-FTS2 micelles (A, B), 
PTX-loaded PEG5K-Fmoc-FTS2 micelles (C, D) and DOX-loaded PEG5K-Fmoc-FTS2 micelles (E, 
F) measured by DLS and TEM, respectively.  
Drug concentration in micelle was kept at 1 mg/mL. Blank micelle concentration was 20 mg/mL. 
 
Table 6. Physicochemical characterization of drug-free and DOX-loaded PEG5k-FTS2 and 
PEG5k-Fmoc-FTS2 micelles. 
Micelles Molar 
Ratio 
Conc. of DOXa) 
(mg/mL) 
Sizeb) 
(nm) 
PDIc) DLCd) 
(%) 
DLEe) 
(%) 
Stabilityf) 
(hour) 
PEG5K-FTS2 - - 17.6 0.20 - - - 
PEG5K-FTS2 : DOX 0.5 :1 1 100.9 0.37 10.2 65.5 30 
PEG5K-FTS2 : DOX  1 :1 1 69.7 0.29 7.5 88.1 48 
PEG5K-FTS2 : DOX  2.5 :1 1 24.2 0.27 3.2 90.2 120 
        
PEG5K-Fmoc-FTS2 - - 24.8 0.22 - - - 
PEG5K-Fmoc-FTS2 : DOX 0.1 :1 1 130.4 0.29 32.8 69.7 20 
PEG5K-Fmoc-FTS2 : DOX 0.25 :1 1 173.9 0.32 17 65.9 48 
PEG5K-Fmoc-FTS2 : DOX 0.5 :1 1 120.0 0.33 10.2 67.8 120 
PEG5K-Fmoc-FTS2 : DOX 1 :1 1 29.23 0.31 6.6 81.2 240 
PEG5K-Fmoc-FTS2 : DOX 2.5 :1 1 25.67 0.21 3.1 91.2 336 
a)DOX concentration in micelle was kept at 1 mg/mL. Blank micelle concentration was 20 
mg/mL. Values reported are the mean ± SD for triplicate samples. b)Measured by dynamic light 
scattering particle sizer. c)PDI = polydispersity index. d)DLC = drug loading capacity. e)DLE = 
drug loading eﬃciency. f)Data means there was no noticeable size change during the follow-up 
period. 
 
 
 
 73 
Table 7. Physicochemical characterization of drug-free and PTX-loaded PEG5k-FTS2 and PEG5k-
Fmoc-FTS2 micelles. 
 
Micelles Molar 
Ratio 
Conc. of 
PTXa) 
(mg/mL) 
Sizeb) 
(nm) 
PDIc) DLCd) 
(%) 
DLEe) 
(%) 
Stabilityf) 
(hour) 
PEG5K-FTS2 - - 17.6 0.20 - - - 
PEG5K-FTS2 : PTX 2.5 :1 1 24.9 0.35 4.5 81.2 2 
PEG5K-FTS2 : PTX 5 :1 1 25.6 0.23 2.8 97.6 20 
        
PEG5K-Fmoc-FTS2 - - 24.8 0.22 - - - 
PEG5K-Fmoc-FTS2 : PTX 0.5 :1 1 36.2 0.19 12.1 55.4 12 
PEG5K-Fmoc-FTS2 : PTX 1 :1 1 29.4 0.11 9.0 73.2 15 
PEG5K-Fmoc-FTS2 : PTX 2.5 :1 1 29.7 0.12 4.6 87.3 17 
PEG5K-Fmoc-FTS2 : PTX 5 :1 1 25.9 0.27 2.6 96.0 48 
 
a)PTX concentration in micelle was kept at 1 mg/mL. Blank micelle concentration was 20 
mg/mL. Values reported are the mean ± SD for triplicate samples. b)Measured by dynamic light 
scattering particle sizer. c)PDI = polydispersity index. d)DLC = drug loading capacity. e)DLE = 
drug loading eﬃciency. f)Data means there was no noticeable size change during the follow-up 
period. 
 
The size, DLC, DLE, and colloidal stability of drug-loaded PEG5K-Fmoc-FTS2 micelles 
were then examined and compared to those of the counterparts without an Fmoc motif. In 
general, incorporation of DOX or PTX led to an increase in the particle sizes for both micellar 
systems. However, the sizes gradually became close to the original size with the increase in 
carrier/drug molar ratio. For DOX, a minimal carrier/drug molar ratio of 0.5:1 was needed to 
formulate the drug in PEG5K-FTS2 micelles (Table 6). In contrast, DOX could be loaded into 
PEG5K-Fmoc-FTS2 micelles at a carrier/drug molar ratio as low as 0.1:1. The DLC for 
DOX/PEG5K-Fmoc-FTS2 mixed micelles at this carrier/drug ratio is 32.8%, which represents a 
3.2-fold increase compared with the PEG5K-FTS2 formulation. In addition, DOX/PEG5K-Fmoc-
FTS2 mixed micelles were significantly more stable than the counterparts without an Fmoc motif 
under all carrier/drug ratios examined (Table 6). Similarly, incorporation of an Fmoc motif 
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significantly improved the performance of PEG5K-FTS2 micelles in formulating PTX (Table 7). 
The DLC for PTX/PEG5K-Fmoc-FTS2 mixed micelles was 12.1%, which is a 2.7-fold increase 
compared with the counterpart without an Fmoc. The morphology and size uniformity were 
largely retained following loading of PTX (Figures 30C and D) or DOX (Figures 30E and F) 
at a respective molar ratio of 2.5:1 and 1:1. Incorporation of an Fmoc group into PEG5K-FTS2 
system led to a significant improvement in drug loading capacity for PTX or DOX and the 
colloidal stability of the resulting drug-loaded micelles was also significantly improved (Tables 
6 and 7). These improvements are likely due to an enhanced drug/carrier interaction. Fmoc 
group contains a bulky, fused fluorenylmethyl ring structure capable of providing strong 
hydrophobic interaction and forming π-π stacking with compounds carrying aromatic moieties 
(Figure 27, unpublished data). 
The CMC of PEG5K-Fmoc-FTS2 micelles was examined using pyrene as a fluorescence 
probe (Figure 31). The CMC of the PEG5K-Fmoc-FTS2 micelles is 0.2 µM (Figure 31), which is 
lower than that of PEG5K-FTS2 micelles (0.68 µM) [67].
 This is due to that Fmoc can not only 
enhance the carrier/drug interaction, but also facilitate the interaction among the carrier 
molecules. The   reduced CMC will improve the stability of PEG5K-Fmoc-FTS2 micelles upon 
dilution in vivo.  
 
Figure 31. CMC of PEG5K-Fmoc-FTS2 micelles 
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4.4.2 In vitro drug release study 
The profile of DOX release from PEG5K-Fmoc-FTS2 micelles was examined by a dialysis 
method and compared to that of DOX-loaded PEG5K-FTS2 micelles. For the initial 8 h, about 
50.7 % of DOX was released from PEG5K-FTS2 formulation while only 38.3 % of DOX was 
released from DOX-loaded PEG5K-Fmoc-FTS2 micelles (Figure 32). Overall, DOX formulated 
in PEG5k-Fmoc-FTS2 micelles exhibited a slower relative rate of DOX release compared to the 
counterpart without an Fmoc motif.  
 
Figure 32. Cumulative DOX release profile from free DOX, DOX-loaded PEG5K-FTS2 and 
PEG5K-Fmoc-FTS2 micelles.DPBS (PH = 7.4) containing 0.5% (w/v) Tween 80 was used as the 
release medium. Values reported are the means ± SD for triplicate samples. 
 
4.4.3 Hemolytic effect of micelles 
Figure 33 shows the hemolytic activities of drug-free PEG5K-Fmoc-FTS2 micelles and 
polyethylenimine (PEI), a cationic polymer known to have significant hemolytic effect [86]. PEI 
induced hemolysis in a dose-dependent manner. In contrast, PEG5K-Fmoc-FTS2 micelles showed 
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only negligible levels of hemolytic activity at the same experimental concentrations, suggesting 
the safe profile of PEG5K-Fmoc-FTS2 micelles. 
 
 
Figure 33. In vitro hemolysis assay of PEG5k-Fmoc-FTS2 micelles compared with PEI with two 
different concentrations (0.2, 1 mg/mL).  
Values reported are the mean ± SD for triplicate samples. 
4.4.4 In vitro cytotoxicity of free and drug-loaded micelles  
The cytotoxicity of drug-free PEG5K-Fmoc-FTS2 and PEG5K-FTS2 micelles was examined in 
4T1.2 and HCT-116 tumor cells and compared to free FTS (Figures 34A and B). Free FTS 
inhibited the tumor cell growth in a concentration-dependent manner. The two FTS conjugates 
were comparable but slightly less active than free FTS in cytotoxicity towards both 4T1.2 and 
HCT-116 tumor cells (Figures 34A and B). Cytotoxicity of PEG5K-FTS2 conjugate was well 
retained following the incorporation of an Fmoc motif (Figures 34A and B). The cytotoxicity of 
PEG5K-Fmoc-FTS2 is unlikely to be attributed to the surface activity since PEG-Fmoc-FTS2 
micelles showed minimal hemolytic activity at the concentrations that were much higher than 
those used in the cytotoxicity study (Figure 33). It is likely that the cytotoxicity of PEG-FTS 
comes from the released FTS following intracellular delivery. This is supported by the 
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observation that a PEG5K-FTS2 conjugate with a relatively labile ester linkage is more active than 
a similar conjugate with a relatively stable amide linkage [67]. 
 
 
Figure 34. Cytotoxicity of drug-free PEG5k-FTS2 and PEG5k-Fmoc-FTS2 micelles compared to 
FTS against 4T1.2 mouse breast cancer cell line (A) and HCT-116 human colon carcinoma cell 
line (B).  
 
Figures 35A-C show the cytotoxicity of Taxol and PTX formulated in PEG5K-Fmoc-FTS2 
micelles in several cancer cell lines. Taxol inhibited the tumor cell growth in a concentration 
dependent manner. Delivery of PTX via PEG5K-Fmoc-FTS2 micelles led to a significant increase 
in the cytotoxicity at low concentrations. We also tested the cytotoxicity of DOX formulated in 
PEG5K-Fmoc-FTS2 micelles and compared to free DOX∙HCl. Similarly, DOX-loaded PEG5K-
Fmoc-FTS2 micelles showed more potent cytotoxicity than free DOX at the low concentration 
range (Figures 35D~F). When PTX or DOX was formulated into the PEG5K-Fmoc-FTS2 
micelles, they showed better cytotoxicity to MCF-7, A549 and HCT-116 cancer cells compared 
with Taxol formulation or free DOX (Figures 35A-F), suggesting that PTX or DOX can be more 
effectively delivered into tumor cells by PEG5K-Fmoc-FTS2 micelles, resulting in enhanced 
tumor cell killing.  
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Figure 35. The anticancer effect of Taxol, drug-free and PTX/ PEG5k-Fmoc-FTS2 micelles. 
Performed on MCF-7 human breast carcinoma cell line (A), A549 human lung 
adenocarcinoma epithelial cell line (B) and HCT-116 human colon carcinoma cell line (C). 
Tumor cell killing of free DOX, drug-free and DOX-loaded PEG5k-Fmoc-FTS2 micelles was 
performed in MCF-7 human breast carcinoma cell line (D), A549 human lung 
adenocarcinoma epithelial cell line (E) and HCT-116 human colon carcinoma cell line (F). Cells 
were treated for 72 h and cytotoxicity was determined by MTT assay. Values reported are the 
means ± SD for triplicate samples. 
4.4.5 Maximum tolerated dose (MTD) studies 
Groups of 4 female CD-1 mice were administered intravenously with a single dose of either 
Taxol (15-25 mg PTX/kg) or PTX-loaded PEG5K-Fmoc-FTS2 micelles (50-140 mg PTX/kg). 
Taxol was well tolerated at the dose of 15 mg PTX/kg (Table 8). However, increasing the PTX 
dosage to 20 mg/kg resulted in the death of 1 out of the 4 treated mice (Table 8). For the mice 
treated with PTX-loaded PEG5K-Fmoc-FTS2 micelles, there was neither significant weight loss 
nor noticeable changes in normal activity at a PTX dosage as high as 140 mg/kg (Table 8). 
Therefore, the MTD for PTX/PEG5K-Fmoc-FTS2 is greater than 140 mg/kg, which is 
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significantly higher than that for Taxol (15-20 mg/kg). Figure 36 shows the result of MTD study 
for DOX-loaded PEG5K-Fmoc-FTS2 micelles. There were no obvious body weight loss and other 
toxicity signs in the mice treated with DOX-loaded PEG5K-Fmoc-FTS2 micelles at the doses of 
5-15 mg DOX/kg within two weeks. Only a moderate body weight loss (<10%) was found in 
mice treated with 20 mg/kg of DOX/PEG5K-Fmoc-FTS2 micelles on day 4, which was recovered 
on day 5. In contrast, although free DOX was well tolerated at the dose of 10 mg/kg, it caused a 
significant decrease (>15%) in the body weight, and eventually the death of all treated mice at a 
dose of 15 mg DOX/kg (Table 8). Thus, the MTD of DOX-loaded PEG5K-Fmoc-FTS2 micelles 
and free DOX is ~20 mg/kg and 10 mg/kg, respectively. Drug (DOX or PTX)-loaded PEG5K-
Fmoc-FTS2 micelles demonstrated an excellent safety profile with a significantly higher MTD 
compared with free drug (Table 8 and Figure 36). This is likely due to a slow relative rate of 
drug release from the micelles before they reach the tumor site, leading to reduced drug uptake 
by normal tissues. 
 
Table 8. Animal deaths in the MTD study 
Formulation Dose 
(mg/kg) 
Animal 
death 
Weight loss 
(%) 
Taxol 15 0/4 -11.2* 
Taxol 20 1/4 N/A 
Taxol 25 3/4 N/A 
PEG5K-Fmoc-FTS2/PTX 50 0/4 -13.1 
PEG5K-Fmoc-FTS2/PTX 75 0/4 -10.8 
PEG5K-Fmoc-FTS2/PTX 100 0/4 -8.3 
PEG5K-Fmoc-FTS2/PTX 120 0/4 -4.5 
PEG5K-Fmoc-FTS2/PTX 140 0/4 -1.6 
 
Free DOX 5 0/4 -17.7 
Free DOX 10 0/4 -11.0 
Free DOX 15 4/4 N/A 
Free DOX 20 4/4 N/A 
PEG5K-Fmoc-FTS2/DOX 5 0/4 -24.2 
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PEG5K-Fmoc-FTS2/DOX 10 0/4 -21.2 
PEG5K-Fmoc-FTS2/DOX 15 0/4 -15.2 
PEG5K-Fmoc-FTS2/DOX 20 0/4 -6.4 
PEG5K-Fmoc-FTS2/DOX 25 4/4 N/A 
PEG5K-Fmoc-FTS2/DOX 30 4/4 N/A 
 
* Negative values reflect the body weight increase. 
 
 
 
Figure 36. Body weight change of normal CD-1 mice (n = 4) administered intravenously with 
equivalent doses of free DOX or DOX-loaded PEG5k-Fmoc-FTS2 micelles in the MTD study. 
4.4.6 NIRF optical imaging 
Biodistribution and tumor-targeting efficiency of PEG5K-Fmoc-FTS2 micelles were tested in a 
human prostate cancer xenograft model (PC-3). DiD, a hydrophobic near infrared fluorescence 
(NIRF) dye with high penetration, low tissue absorption and scattering was loaded into the 
PEG5K-Fmoc-FTS2 micelles for tissue imaging. Figure 37A shows that DiD-loaded PEG5K-
Fmoc-FTS2 micelles were able to accumulate at the tumor as early as 6 h post injection, and 
these micelles retained in the tumor at 96 h after injection. No obvious tumor accumulation was 
observed in the mice treated with free DiD dye [18]. After last imaging at 96 h post-injection, 
tumors and major organs were excised for ex vivo imaging. As shown in Figure 37B & C, 
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significantly higher levels of signal were observed in the tumor tissues compared with normal 
organs except the lung. The very small size of our micellar system may contribute significantly 
to the effective tumor localization (Figure 37A). Interestingly, little fluorescence signal was 
observed in liver and spleen, the two major internal organs that are involved in the nonspecific 
clearance of nanoparticles.  
 
Figure 37. In vivo (A) and ex vivo (B) NIRF imaging of DiD-loaded PEG5k-Fmoc-FTS2 micelles 
in prostate cancer PC-3 xenograft-bearing mice. Quantitative fluorescence intensities of tumors 
and major organs from ex vivo images at 24 h (C).  
4.4.7 Plasma pharmacokinetics and tissue distribution 
Free DOX·HCl and DOX-loaded PEG5K-Fmoc-FTS2 micelles were injected to tumor-free mice 
at a dose of 5 mg/kg, and the DOX concentration in plasma was measured at different time 
points. Figure 38A shows the % of injected dose of DOX in the blood over time following i.v. 
administration. The pharmacokinetic parameters were calculated based on a non-compartment 
model and summarized in Table 9. The T1/2 of DOX in DOX-loaded PEG5K-Fmoc-FTS2 
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micelles was 6.7-fold higher than that of free DOX. Furthermore, the plasma AUC0-inf of DOX 
for the micellar DOX was almost 19-fold higher than that of free DOX (64.8 vs 3.43 µg x h/mL). 
In contrast, the Vd of DOX for micellar DOX was significantly lower than that of free DOX 
(2.58 vs 7.34 L/kg), suggesting prolonged blood circulation of DOX-loaded PEG5K-Fmoc-FTS2 
micelles. 
 
Figure 38. Blood retention kinetics of DOX∙HCl and DOX-loaded PEG5k-Fmoc-FTS2 micelles 
in mice (A).  
DOX∙HCl and DOX- loaded PEG5K-Fmoc-FTS2 micelles were injected into female BALB/c 
mice via tail vein at a dose of 5 mg DOX/kg. Tissue distribution of DOX 1 day following the 
injection (B). DOX∙HCl and DOX-loaded PEG5K-Fmoc-FTS2 were injected into female 
BALB/c mice bearing 4T1.2 breast tumor at the dose of 5 mg DOX/kg, respectively. Values are 
means ± SEM. 
 
 
Table 9. Pharmacokinetic variables of free DOX and DOX-loaded PEG5k-Fmoc-FTS2 micelles 
Groups T1/2 
(h) 
AUC0-inf 
(µg×h/mL) 
Cmax 
(µg/mL) 
CL 
(L/h/kg) 
Vd  
(L/kg) 
DOX 1.74 3.43 3.59 2.91 7.34 
PEG5K-Fmoc-FTS2/DOX 11.60 64.80 25.84 0.15 2.58 
 
The tissue distribution of DOX·HCl and DOX-loaded PEG5K-Fmoc-FTS2 micelles was also 
investigated in female BALB/c mice bearing 4T1.2 breast tumor. Free DOX·HCl and DOX-
loaded PEG5K-Fmoc-FTS2 micelles were injected at the same DOX dose of 5 mg/kg. At 24h 
post-injection, major organs and tumors were excised for DOX determination. As shown in 
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Figure 38B, there was about 2-fold increase in the tumor uptake of DOX for DOX-loaded 
PEG5K-Fmoc-FTS2 micelles compared to free DOX. In addition, DOX-loaded PEG5K-Fmoc-
FTS2 micelles were associated with a reduced DOX accumulation in normal organs such as heart 
compared to free DOX (Figure 38B). These findings showed that DOX-loaded PEG5K-Fmoc-
FTS2 can not only increase the tumor-target efficacy of DOX, but also decrease DOX-associated 
cardiotoxicity.  
4.4.8 In vivo therapeutic study 
The antitumor activity of PTX- and DOX-loaded PEG5K-Fmoc-FTS2 micelles was first 
investigated in a syngeneic murine breast cancer model (4T1.2). As shown in Figure 39A, free 
PEG5K-Fmoc-FTS2 micelles alone showed no effects in inhibiting the tumor growth at the dose 
used. Taxol formulation showed a modest effect in inhibiting the tumor growth at a dose of 10 
mg PTX/kg. In contrast, PTX formulated in PEG5K-Fmoc-FTS2 micelles showed a much more 
pronounced antitumor activity at the same dosage. It is also apparent that PTX/PEG5K-Fmoc-
FTS2 mixed micelles were more active than the counterpart without an Fmoc motif (P < 0.05). 
Increasing the PTX dosage to 20 mg/kg resulted in a further improvement in the therapeutic 
effect. 
Figure 39C shows the result of therapy study on DOX/PEG5K-Fmoc-FTS2 micelles in 
4T1.2 tumor model. Both DOX/PEG5K-FTS2 and DOX/PEG5K-Fmoc-FTS2 were significantly 
more active than free DOX or liposomal DOX in inhibiting the tumor growth. There was also a 
trend of improvement in antitumor activity for DOX/PEG5K-Fmoc-FTS2 compared to 
DOX/PEG5K-FTS2 although it is not statistically significant (P = 0.16). No significant changes 
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were noticed in body weight in all treatment groups compared to PBS control group (Figure 39B 
and D).  
 
 
Figure 39. Enhanced antitumor activity of PTX formulated in PEG5K-Fmoc-FTS2 micelles in a 
syngeneic murine breast cancer model (4T1.2) (A). Changes of body weight in mice receiving 
different treatments (B).  
P < 0.01 (10 mg PTX/kg PEG5K-Fmoc-FTS2 vs. Taxol), P < 0.05 (10 mg PTX/kg PEG5K-Fmoc-
FTS2 vs. 10 mg PTX/kg PEG5K-FTS2). Enhanced antitumor activity of DOX formulated in 
PEG5K-Fmoc-FTS2 micelles in a syngeneic murine breast cancer model (4T1.2) compared to 
DOX∙HCl and DOX-loaded liposome (C). Changes of body weight in mice receiving different 
treatments (D). P < 0.01 (5 mg DOX/kg PEG5K-Fmoc-FTS2 vs. DOX∙HCl), P < 0.01 (5 mg 
DOX/kg PEG5K-Fmoc-FTS2 vs. 5 mg DOX/kg liposome). 
 
The in vivo therapeutic activity of PTX formulated in PEG5K-Fmoc-FTS2 micelles was further 
evaluated in a human prostate cancer xenograft model (PC-3) (Figure 40A). PC-3 model has a 
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relatively slower growth rate than 4T1.2 tumor model and tumor growth was more effectively 
controlled by the different treatments in PC-3 model. Nonetheless, PTX/PEG5K-Fmoc-FTS2 
mixed micelles were significantly more effective than either Taxol or PTX/PEG5K-FTS2 mixed 
micelles in inhibiting the tumor growth at the same dose of 10 mg PTX/kg. Figure 9C shows 
representative images of nude mice bearing PC-3 tumors treated with PBS and various PTX 
formulations by day 17 after initial treatment. By day 17, the RTV for PTX/PEG5K-Fmoc-FTS2 
mixed micelles was 1.71, while the RTVs for mice treated with Taxol and PTX/PEG5K-FTS2 
mixed micelles were 5.2, and 2.9, respectively. Increasing the dose of PTX to 20 mg PTX/kg led 
to a further improvement in antitumor activity, one out of the 5 mice in this group became tumor-
free after day 38 without further treatment. No weight loss was observed in mice treated with all 
PTX formulations (Figure 40B), while consistent weight loss was shown in mice treated with 
PBS or carrier alone after day 9 (Figure 40B).  
        In vivo therapy study demonstrated that significant therapeutic effect can be achieved with 
minimal toxicity using our PEG5K-Fmoc-FTS2 micellar system (Figures 39 and 40) in both 
prostate and breast cancer models. The superior antitumor efficacy along with the minimal 
toxicity of the improved system could be ascribed to an enhanced stability, a decreased relative 
rate of drug release and an improved pharmacokinetic profile, leading to effective tumor 
targeting and reduced nonspecific uptake by normal tissues. 
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Figure 40. Enhanced antitumor activity of PTX formulated in PEG5K-Fmoc-FTS2 micelles in a 
human prostate cancer xenograft model (PC-3) (A). Changes of body weight in mice receiving 
different treatments (B).  
P < 0.01 (10 mg PTX/kg PEG5K-Fmoc-FTS2 vs. Taxol), P < 0.01 (10 mg PTX/kg PEG5K-Fmoc-
FTS2 vs. 10 mg PTX/kg PEG5K-FTS2). Photograph showing representative images of nude 
mice bearing PC-3 tumors treated with PBS and different PTX formulations by day 17 after 
initial treatment (C). 
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5.0  REDUCTION-SENSITIVE DUAL FUNCTIONAL NANOMICELLES FOR 
IMPROVED DELIVERY OF PACLITAXEL 
5.1 ABSTRACT 
We have developed a dual-functional nanocarrier composed of a hydrophilic polyethylene glycol 
(PEG) and a hydrophobic farnesylthiosalicylate (FTS, a nontoxic Ras antagonist), which is 
effective in delivery of hydrophobic anticancer drug, paclitaxel (PTX). To facilitate the retention 
of the therapeutic activity of the carrier, FTS was coupled to PEG via a reduction-sensitive 
disulfide linkage (PEG5k-S-S-FTS2). PEG5k-S-S-FTS2 conjugate formed uniform micelles with 
very small size (∼30 nm) and the hydrophobic drug PTX could be readily incorporated into the 
micelles. Interestingly, inclusion of a disulfide linkage into the PEG5k-FTS2 micellar system 
resulted in a 4-fold decrease in the critical micelle concentration (CMC). In addition, the PTX 
loading capacity and colloidal stability of PTX-loaded micelles were improved. HPLC-MS 
showed that parent FTS could be more effectively released from PEG5k-S-S-FTS2 conjugate in 
tumor cells/tissues compared to PEG5k-FTS2 conjugate in vitro and in vivo. PEG5k-S-S-FTS2 
exhibited a higher level of cytotoxicity toward tumor cells than PEG5k-FTS2 without a disulfide 
linkage. Furthermore, PTX-loaded PEG5k-S-S-FTS2 micelles were more effective in inhibiting 
the proliferation of cultured tumor cells compared to Taxol and PTX loaded in PEG5k-FTS2 
micelles. More importantly, PTX-loaded PEG5k-S-S-FTS2 micelles demonstrated superior 
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antitumor activity compared to Taxol and PTX formulated in PEG5k-FTS2 micelles in an 
aggressive murine breast cancer model (4T1.2). 
5.2 BACKGROUND 
Polymeric micelles are an attractive delivery system due to their easy preparation, small sizes 
(10-100 nm), and their ability to solubilize hydrophobic drugs and accumulate preferentially 
within tumors [45, 97, 98, 102, 118]. We previously developed a nanocarrier based on 
polyethylene glycol (PEG)-derivatized farnesylthiosalicylate (FTS) [67]. PEG5k-FTS2 readily 
formed micelles (20~30 nm) that were highly efficient in loading hydrophobic anticancer drugs 
such as paclitaxel (PTX) [67]. More importantly, PTX-loaded PEG5k-FTS2 micelles achieved 
enhanced antitumor efﬁcacy compared to Taxol formulation in vivo [67]. Different from most of 
the existing drug carriers that lack therapeutic effect, PEG5k-FTS2 itself exhibits antitumor 
activity [67]. FTS is a potent and especially nontoxic Ras antagonist [51, 103]. Ras gene 
mutations can be found in one-third of human cancers, with the highest incidence in 
adenocarcinomas of the pancreas (90%), colon (50%) and the lung (30%) tumor [52]. FTS can 
effectively inhibit the growth of many different types of tumors via inhibition of Ras-dependent 
signaling involved in tumor maintenance and progression [121]. The mechanism involves the 
dislodgement of Ras from the cell membrane and subsequent degradation of the protein [55, 84]. 
As a dual function carrier, the cleavability of the linkage between PEG and FTS in 
PEG5k-FTS2 conjugate is critical for its biological activity. In our previous study, we compared 
the antitumor activity of a conjugate with a labile ester linkage, PEG5K-FTS2(L), with that of a 
similar conjugate with a relatively stable amide linkage, PEG5K-FTS2(S) [67]. PEG5K-FTS2(L) 
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alone showed a significantly higher level of cytotoxicity towards tumor cells compared to 
PEG5K-FTS2(S) presumably due to a more readily release of FTS from PEG5K-FTS2(L) inside 
tumor cells [67]. In addition, delivery of PTX via PEG5K-FTS2(L) micelles led to an improved 
antitumor activity in vivo over PTX formulated in PEG5K-FTS2(S) micelles [67]. 
In this study, we propose to incorporate into PEG5K-FTS2(L) an additional cleavable 
linkage (disulfide bond) to further facilitate the release of FTS following intracellular delivery to 
tumor cells. We choose disulfide linkage because tumor cells have significantly higher 
concentrations of glutathione (GSH) than those in the extracellular fluids and disulfide linkage 
has been widely used to develop a reduction-sensitive delivery system to facilitate drug release at 
tumor sites [13, 49, 50, 110, 122-129]. Our data showed that incorporation into PEG5K-FTS2(L) a 
disulfide linkage led to an enhanced release of FTS inside tumor cells, which was associated with 
an improved cytotoxicity against tumor cells. Interestingly, the conjugate with a disulfide linkage 
(PEG5k-S-S-FTS2) exhibited a reduced critical micelle concentration (CMC) in addition to 
improved drug loading capacity and formulation stability. Finally, paclitaxel (PTX) formulated 
in PEG5k-S-S-FTS2 micelles was significantly more effective than the PEG5K-FTS2(L) 
formulation in inhibiting the tumor growth in a murine breast cancer model (4T1.2).  
5.3 EXPERIMENTAL PROCEDURES 
5.3.1 Materials 
Paclitaxel (98%) was purchased from AK Scientific Inc. (CA, USA). FTS and PEG5K-FTS2 
conjugate were synthesized according to published literature [67, 103]. Poly(ethylene glycol) 
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methyl ether (MeO-PEG-OH, MW=5000 kDa), dimethyl sulfoxide (DMSO), succinate 
anhydride, diethanolamine, trypsin-EDTA solution, Dulbecco’s Modified Eagle’s Medium 
(DMEM) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were all 
purchased from Sigma-Aldrich (MO, USA). Di-Boc-lysine, triethylamine (TEA) and 
trifluoroacetic acid (TFA) were obtained from Acros Organic (NJ, USA). Bis(2-
hydroxyethyl) disulfide, dicyclohexylcarbodiimide (DCC) and N-hydroxysuccinimide (NHS) 
were purchased from Alfa Aesar (MA, USA). 4-(dimethylamino) pyridine (DMAP) was 
purchased from Calbiochem-Novabiochem Corporation (CA, USA). All solvents used in this 
study were HPLC grade. 
5.3.2 Cell culture 
MCF-7 is a human breast carcinoma cell line. 4T1.2 is a mouse metastatic breast cancer cell line. 
HCT-116 is a human colon carcinoma cell line. PC-3 and DU-145 are human prostate cancer 
cell lines. All cell lines were cultured in DMEM containing 5% FBS and 1% penicillin-
streptomycin at 37 ℃ in a humidified 5 % CO2 atmosphere. 
5.3.3 Animals 
Female BALB/c mice, 4-6 weeks in age, were purchased from Charles River (Davis, CA). All 
animals were housed under pathogen-free conditions according to AAALAC guidelines. All 
animal-related experiments were performed in full compliance with institutional guidelines and 
approved by the Animal Use and Care Administrative Advisory Committee at the University of 
Pittsburgh. 
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5.3.4 Synthesis of PEG5K-S-S-FTS2 conjugate 
Figure 41 shows the synthesis route of PEG5K-S-S-FTS2 conjugate. Synthesis and structural 
characterizations are detailed below. 
Compound 1:  Bis(2-hydroxyethyl) disulfide (1.54 g, 10 mmol) was added to a solution of FTS 
(3.58 g, 10 mmol), DCC (3.09 g, 15 mmol), DMAP (122 mg, 1 mmol) in CH2Cl2 (50 mL). The 
mixture was stirred at room temperature until TLC showed completion of reaction. The mixture 
was filtered through cotton and the filtrate was concentrated on a rotary evaporator. The residue 
was chromatographed (1:4 EtOAc/PE) on silica gel to afford the compound 1 (3.2 g, 6.5 mmol, 
65%). 1H NMR (400 MHz, CDCl3)  δ 7.99-7.97 (m, 1H), 7.45-7.41 (m, 1H), 7.32-7.28 (m, 1H), 
7.17-7.13 (m, 1H), 5.36-5.32 (m, 1H), 5.10-5.07 (m, 2H), 4.59(t, J = 6.8 Hz, 2H), 3.88-3.87 (m, 
2H), 3.58-3.56 (m, 2H), 3.06 (t, J = 6.8 Hz, 2H), 2.89 (t, J = 6 Hz, 2H), 2,.09-1.97(m, 8H), 
1.73(s, 3H), 1.68(s, 3H), 1.60(s, 6H). 
Compound 2:  Succinic anhydride (2 g, 20 mmol) was added to a solution of compound 1 (4.94 
g, 10 mmol), DMAP (2.44 g, 20 mmol) in CHCl3 (50 mL), and the mixture was refluxed until 
TLC showed completion of reaction. The mixture was concentrated on a rotary evaporator and 
the residue was chromatographed (1:1 EtOAc/PE) on silica gel to afford the compound 2 (5.8 g, 
6.5 mmol, 97%). 1H NMR (400 MHz, CDCl3) δ 7.99-7.97 (m, 1H), 7.41-7.38 (m, 1H), 7.29-7.27 
(m, 1H), 7.14-7.10 (m, 1H), 5.30-5.27 (m, 1H), 5.06-5.03 (m, 2H), 4.54(t, J = 6.8 Hz, 2H), 
4.33(t, J = 6.8 Hz, 2H), 3.55-3.53 (m, 2H), 3.03 (t, J = 6.4 Hz, 2H), 2.89 (t, J = 6.4 Hz, 2H), 
2.62-2.61 (m, 4H), 2.04-1.92(m, 8H), 1.69(s, 3H), 1.64(s, 3H), 1.55(s, 6H). 
Compound 5: Compound 5 was synthesized from compound 3 following a published method 
[67]. 
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Compound 6: DCC, DMAP, compound 2, and compound 5 were dissolved in CH2Cl2 with a 
molar ratio of 1:6:3:0.3 and allowed to react overnight at room temperature. The solution was 
filtered and precipitated in diethyl ether and ethanol twice, respectively. The compound 6 was 
obtained by further drying under vacuum.  
 
 
Figure 41. Synthesis scheme of PEG5k-S-S-FTS2 conjugate 
5.3.5 Preparation and characterization of PTX-loaded PEG5K-S-S-FTS2 micelles 
PTX-solubilized PEG5K-S-S-FTS2 micelles were prepared via a solvent evaporation method 
following our published protocol [13, 67]. Briefly, PTX (10 mM in chloroform) and PEG5K-S-S-
FTS2 conjugate (10 mM in chloroform) were mixed with various carrier/drug ratios. A film of 
drug/carrier mixture was formed by removed the organic solvent and the film was further dried 
under vacuum. PTX-loaded micelles were formed by adding DPBS to hydrate the thin film 
followed by gentle vortexing. The PTX loading efficiency was measured by high performance 
liquid chromatography (HPLC) (Alliance 2695-2998 system) as described previously [67]. Drug 
 93 
loading capacity (DLC) and drug loading efficiency (DLE) were calculated according to the 
following equation:  
DLC (%) = [weight of drug used/(weight of polymer + drug used)] ×100% 
DLE (%) = (weight of loaded drug/weight of input drug) ×100% 
Morphology, micelle size, and size distribution were assessed by transmission electron 
microscopy (TEM) and dynamic light scattering (DLS) following our published protocol [118]. 
The critical micelle concentration (CMC) of PEG5K-S-S-FTS2 micelles was determined using 
pyrene as a fluorescence probe [80]. 
5.3.6 Release of FTS from the PEG5K-S-S-FTS2 and PEG5K-FTS2 conjugates 
DU-145 and PC-3 cells were seeded in 6-well plates. After 24 h of incubation in DMEM with 
5% FBS, the old medium was removed and the cells were incubated for 72 h in the presence of 
drug-free PEG5K-S-S-FTS2 or PEG5K-FTS2 micelles. The cells were washed with ice-cold PBS 
three times and solubilized via a mixture of MeOH and H2O. The lysates were vortexed and then 
centrifuged at 14,000 rpm for 10 mins at 4 °C. Supernatants were transferred to another set of 
1.5-mL microtubes and stored at -80 °C for MS analysis. The amount of FTS in each sample was 
quantified by Waters' SYNAPT G2-S Mass Spectrometer according to the literature [87, 130]. 
Chromatographic separation of FTS was performed on an Acquity UPLC BEH C18 column (2.1 
× 50 mm, 1.7 µm, Waters).  The mobile phase A (MPA) was 0.1% formic acid in acetonitrile, 
and mobile phase B was 0.1% formic acid in water. The flow rate of mobile phase was 0.40 
mL/min and the column temperature was maintained at 50°C. Data were processed using 
QuanLynx (v4.1, Waters). Extracted ion chromatograms (EICs) were extracted using a 20 mDa 
window centered on the expected m/z 357.189 for FTS. 
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Similarly, FTS release was examined with tumor tissues from female BALB/c mice 
bearing 4T1.2 tumor (~1 cm). Groups of 4 mice received i.v. injection of PEG5K-FTS2 or PEG5K-
S-S-FTS2 conjugate at a dose of 58.5 μmol/kg. One day post injection, blood and tumors were 
collected. Samples were homogenized with PBS, and then mixed with 2 volumes of acetonitrile. 
The mixture was vortexed for 1 min, incubated for 5 mins and centrifuged at 14,000 rpm for 10 
mins at 4°C. The supernatants were decanted from each sample into a clean centrifugation tube 
for MS analysis and FTS was then analyzed as described above.  
5.3.7 In vitro cytotoxicity study 
The cytotoxicity of PTX formulated in PEG5K-S-S-FTS2 micelles was assessed with several 
cancer cell lines and compared to Taxol and PTX loaded in PEG5K-FTS2 micelles, respectively. 
Briefly, MCF-7 cells (5000 cells/well) and HCT-116 cells (1000 cells/well) were seeded in 96-
well plates. After incubation in DMEM with 5% FBS and 1% streptomycin-penicillin for 24 h, 
the old medium was removed and the cells were further incubated for 3 days in the presence of 
indicated concentrations of PTX formulated in Cremophor/EL, PEG5K-S-S-FTS2 or PEG5K-FTS2 
micelles. Cell viability was then assessed by MTT assay following our published literature.6 
Similarly, the cytotoxicity of drug-free PEG5K-S-S-FTS2 micelles was examined and compared 
to free FTS and PEG5K-FTS2 micelles as described above. 
5.3.8 In vivo therapeutic study 
An aggressive murine breast cancer model (4T1.2) was used to examine the in vivo therapeutic 
effect of different formulations of PTX. Tumors were induced by inoculation of 4T1.2 cells (1 x 
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105) in 100 μL PBS at the right flank of female BALB/c mice. After tumors in the mice reached 
a tumor volume of ~ 40 mm3, treatments were started and this day was designated as day 1. On 
the first day, tumor (4T1.2)-bearing mice were randomly divided into five groups (n=5) and 
administered i.v. with PBS (control), drug-free PEG5K-S-S-FTS2 micelles, Taxol (10 mg 
PTX/kg), PTX-loaded PEG5K-FTS2 and PEG5K-S-S-FTS2 micelles (10 mg PTX/kg), respectively 
on days 1, 3, 6, 8, 10 and 12. Tumor sizes were measured twice a week and tumor volumes were 
calculated by the formula: (L×W2)/2, where L and W represent the longest and shortest in tumor 
diameters (mm). Each group was compared by relative tumor volume (RTV) (where RTV equals 
to the tumor volume divided by the initial tumor volume before treatment). The body weights of 
all mice from each group were measured twice a week. 
5.3.9 Statistical analysis 
Data are presented as mean ± standard deviation (SD). Statistical analysis was performed by 
Student’s t-test for comparison of two groups, and comparisons for multiple groups were made 
with one-way analysis of variance (ANOVA), followed by Newman-Keuls test if the overall P < 
0.05. In all statistical analysis, the threshold of significance was defined as P < 0.05. 
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5.4 RESULTS  
5.4.1 Synthesis of PEG5K-S-S-FTS2 conjugate 
To facilitate the retention of the antitumor activity of FTS, a cleavable disulfide linkage was used 
to couple FTS to a hydrophilic PEG (PEG5K-S-S-FTS2). The chemical structure of PEG5K-S-S-
FTS2 is shown in Figure 41. As shown in 
1H NMR spectra (Figure 42), the signals at 3.63 ppm 
and 7-8 ppm were attributed to the methylene protons located at the terminus of PEG and the 
benzene ring protons of FTS, respectively. Additionally, the chemical shift of -CH2-S-S-CH2- 
(2.9-3.1 ppm) could be observed, which confirmed the presence of a disulfide linkage (Figure 
S1). The molecular weight of PEG5K-S-S-FTS2 was determined by MALDI-TOF Mass 
Spectrometry (Figure 43), which is close to the theoretical value of PEG5K-S-S-FTS2. Both
 1H 
NMR and MALDI-TOF Mass spectra indicated the successful synthesis of PEG5K-S-S-FTS2 
conjugate. 
 
 
Figure 42. 1H NMR spectra (400MHz) of PEG5K-S-S-FTS2 conjugate in CDCl3 
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Figure 43. MADLI-TOF of PEG5K-S-S-FTS2 conjugate 
5.4.2 Characterization of PTX-free and PTX/PEG5K-S-S-FTS2 micelles 
PEG5K-S-S-FTS2 was soluble in aqueous solution and readily self-assembled to form micelles 
with size around 30 nm (Figure 44A). Figure 2C shows the TEM images of PEG5K-S-S-FTS2 
micelles. Spherical particles of uniform size were observed and the sizes of the particles 
observed under TEM were consistent with those measured by DLS. Figure 45 shows the CMCs 
of PEG5K-FTS2 and PEG5K-S-S-FTS2 micelles using pyrene as a fluorescence probe. It is 
interesting to notice that incorporation into PEG5K-FTS2 a disulfide linkage led to a ~4-fold 
decrease in CMC. PTX can be readily loaded into PEG5K-S-S-FTS2 micelles. The spherical 
shape and size of the micelles were well retained following incorporation of PTX (Figures 44B 
and D). We then evaluated the loading capacity and stability of PTX-loaded PEG5K-S-S-FTS2 
micelles and compared to those of PEG5K-FTS2 formulation. As shown in Table 10, PTX could 
be loaded in PEG5K-S-S-FTS2 micelles at a carrier/drug molar ratio as low as 1/1. In contrast, a 
minimal carrier/drug molar ratio of 2.5/1 was needed to formulate PTX in PEG5K-FTS2 micelles. 
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Increasing the carrier/drug molar ratio was associated with an improvement in both drug loading 
efficiency (DLE) and the colloidal stability of PTX-loaded micelles (Table 10). In addition, 
PTX-loaded PEG5K-S-S-FTS2 micelles showed better colloidal stability than PEG5K-FTS2 
formulation at all carrier/drug ratios examined (Table 10). 
 
Figure 44. Particle size distribution of PTX-free PEG5K-S-S-FTS2 (A), and PTX-loaded PEG5K-
S-S-FTS2 micelles (B). TEM images of PTX-free PEG5K-S-S-FTS2 (C), and PTX-loaded PEG5K-
S-S-FTS2 micelles (D). 
 
 
Figure 45. Critical micelle concentration (CMC) of PEG5K-S-S-FTS2 (A) and PEG5K-FTS2 (B) 
micelles. 
 
Table 10. Physicochemical characterization of free drug and PTX-loaded PEG5k-FTS2 and 
PEG5k-S-S-FTS2 micelles. 
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Micelles Molar 
ratio 
Conc. of PTX a 
(mg/mL) 
Size b 
(nm) 
PDIc DLC d 
(%) 
DLE e 
(%) 
Stability f 
(hour) 
PEG5K-FTS2 - - 17.6 0.20 - - - 
PEG5K-FTS2 : PTX 2.5 :1 1 24.9 0.35 5.5 81.2 2 
PEG5K-FTS2 : PTX 5 :1 1 25.6 0.23 2.8 97.6 20 
        
PEG5K-S-S-FTS2 - - 32.4 0.21 - - - 
PEG5K-S-S-FTS2 : PTX 1 :1 1 28.5 0.22 12 85.2 1 
PEG5K-S-S-FTS2 : PTX 2.5 :1 1 32.0 0.30 5.2 89.7 3.5 
PEG5K-S-S-FTS2 : PTX 5 :1 1 30.2 0.35 2.6 94.8 30 
 
aPTX concentration in micelle was kept at 1 mg/mL. Blank micelle concentration was 20 mg/mL. 
Values reported are the mean ± SD for triplicate samples. bMeasured by dynamic light scattering 
particle sizer. cPDI = polydispersity index. dDLC = drug loading capacity. eDLE = drug loading 
eﬃciency. fData means there was no noticeable size change during the follow-up period. 
5.4.3 In vitro cytotoxicity of drug-free micelles 
The antitumor activities of two PTX-free micelles, PEG5K-S-S-FTS2 and PEG5K-FTS2, were 
tested in HCT-116 and DU-145 cancer cell lines and compared to free FTS (Figure 46). PEG5K-
FTS2 conjugate with an ester linkage was used as a reduction-insensitive control. As shown in 
Figure 46A, free FTS inhibited the HCT-116 cell growth in a concentration-dependent manner. 
PEG5K-FTS2 with a reduction-insensitive ester linkage was less active than free FTS in 
cytotoxicity (Figure 46A). Interestingly, incorporation into PEG5K-FTS2 an additional disulfide 
linkage led to a significant improvement in cytotoxicity compared to both free FTS and PEG5K-
FTS2 (Figure 46A). Similar result was observed in DU-145 cell line (Figure 46B).  
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Figure 46. Cytotoxicity of drug free PEG5k-FTS2 and PEG5K-S-S-FTS2 micelles in comparison 
to free FTS in HCT-116 human colon carcinoma cell line (A) and DU-145 human prostate 
cancer cell line (B).  
Cells were treated for 72 h and cytotoxicity was determined by MTT assay.  
5.4.4 Release of FTS from the PEG5K-S-S-FTS2 and PEG5K-FTS2 conjugates 
To investigate whether the improved cytotoxicity of PEG5K-S-S-FTS2 over PEG5K-FTS2 is 
attributed to a more effective release of FTS, HPLC-MS was employed to analyze FTS release 
inside PC-3 or DU-145 human prostate cancer cells 72 h following treatment with PEG5K-FTS2 
or PEG5K-S-S-FTS2 micelles. We focused on the detection of the signal of parent FTS. The FTS 
extraction protocol had minimal impact on the integrity of PEG5K-S-S-FTS2 as demonstrated in a 
preliminary study (data not shown). Figure 47A shows that incorporation into PEG5K-FTS2 a 
disulfide linkage led to a 2 to 3-fold increase in the amounts of free FTS detected in PC-3 cells 
(Figure 47A). Similar result was observed in DU-145 cell line (Figure 47B). We also conducted 
a preliminary study on the release of FTS in tumor tissues in vivo. Female BALB/c mice bearing 
4T1.2 tumor (~1 cm) received i.v. injection of PEG5K-S-S-FTS2 and PEG5K-FTS2 micelles at the 
same dose and the amounts of free FTS in the tumor tissues were examined 24 h later. As shown 
in Figure 48, a strong signal of FTS was detected in the tumor tissues while very little FTS 
signal was found in the blood. It is also apparent that significantly greater amounts of free FTS 
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were found in the tumors treated with PEG5K-S-S-FTS2 compared to the PEG5K-FTS2-treated 
tumors (Figure 48), implicating that FTS is more readily cleaved from PEG5K-S-S-FTS2 
micelles at the tumor sites. 
 
Figure 47. HPLC analysis of the amounts of released free FTS in PC-3 or DU-145 prostate 
cancer cells 72 h following treatment with PEG5K-S-S-FTS2 or PEG5K-FTS2 at a FTS 
concentration of 20 μM.   
 
 
Figure 48. HPLC-MS analysis of FTS in blood and tumors 24 h following i.v. administration of 
PEG5K-FTS2 and PEG5K-S-S-FTS2.   
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5.4.5 In vitro cytotoxicity of drug-loaded micelles 
Figure 49 shows the in vitro cytotoxicity of PTX formulated in PEG5K-FTS2 or PEG5K-S-S-FTS2 
micelles, in comparison with Taxol formulation in MCF-7 and HCT-116 cells. Taxol inhibited 
the proliferation of MCF-7 breast cancer cells in a concentration dependent manner (Figure 
49A). Delivery of PTX via PEG5K-FTS2 micelles led to a slight increase in cytotoxicity against 
MCF-7 tumor cells. More importantly, PTX formulated in PEG5K-S-S-FTS2 micelles were more 
active than both Taxol formulation and PTX-loaded PEG5K-FTS2 micelles in inhibiting the tumor 
cell growth, particularly at low PTX concentrations (Figure 49A). Similar result was observed in 
a colon carcinoma cell line, HCT-116 (Figure 49B). 
 
 
Figure 49. Cytotoxicity of PTX-loaded PEG5k-FTS2 and PEG5k-S-S-FTS2 micelles in 
comparison to Taxol formulation in MCF-7 human breast carcinoma cell line (A) and HCT-116 
human colon carcinoma cell line (B). Cells were treated for 72 h and cytotoxicity was 
determined by MTT assay.  
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5.4.6 In vivo therapeutic study 
Figure 50 shows the in vivo therapeutic activity of PTX formulated in PEG5K-S-S-FTS in an 
aggressive murine breast cancer model (4T1.2). PEG5K-S-S-FTS2 micelles alone showed no 
effects in inhibiting the tumor growth at the concentration used. This is due to a relatively low 
concentration of FTS in this group. Taxol formulation showed a modest tumor growth inhibition 
at a dose of 10 mg PTX/kg (Figure 50A). In contrast, both PTX-loaded PEG5K-FTS2 and PEG5K-
S-S-FTS2 micelles were more effective than Taxol formulation at the same dose (Figure 50A). 
More importantly, PTX formulated in PEG5K-S-S-FTS2 micelles exhibited even more potent 
tumor growth inhibition than PTX-loaded PEG5K-FTS2 micelles (P < 0.05) (Figure 50A). No 
significant changes in body weight were detected in all treatment groups compared to PBS 
control group (Figure 50B). 
 
Figure 50. Antitumor activity of PTX formulated in PEG5K-S-S-FTS2 micelles in a syngeneic 
murine breast cancer model (4T1.2) (A). Changes of body weight in mice receiving different 
treatments (B). 
P < 0.05 (PTX/ PEG5K-S-S-FTS2 vs. PTX/ PEG5K-FTS2). N = 5.  
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5.5 DISCUSSION 
We have previously reported that PTX-loaded PEG5K-FTS2(L) micelles showed better antitumor 
activity than Taxol formulation, which could be ascribed to their preferential tumor accumulation 
and a possible synergistic effect between PEG5K-FTS2(L) carrier and loaded PTX [67]. In this 
study, we have shown that inclusion of a disulfide linkage led to a further improvement in the 
therapeutic activity compared to PTX formulated in PEG5k-FTS2(L) micelles and Taxol in vivo 
(Figure 49).  
Similar to PEG5K-FTS2(L), PEG5K-S-S-FTS2 readily self-assembled to form micelles in 
aqueous solution with relatively small size (~30 nm) (Table 10). Such small size shall enable the 
carrier to be highly effective in passive accumulation and deep penetration into solid tumors, 
including poorly vascularized tumors [32, 98]. Interestingly, inclusion of a disulfide linkage led 
to an improvement in both PTX loading capacity and the colloidal stability of PTX-loaded 
micelles (Table 10). We further noticed that incorporation into PEG5K-FTS2(L) a disulfide 
linkage resulted in a 4-fold decrease in CMC (Figure 45). A lower CMC will enable the micelles 
more stable in the blood circulation following systemic administration [131]. This is likely due to 
an improved cooperation in both carrier/carrier and carrier/drug interactions following 
incorporation of a flexible disulfide linkage into the lipid motif of the carrier. The increase in the 
chain length of lipid motif following inclusion of a disulfide linkage may also contribute to the 
improved PTX loading capacity and formulation stability. 
HPLC-MS analysis showed that parent FTS can be detected from cultured cancer cells 
following treatment with PEG5K-FTS2(L) micelles (Figure 47), suggesting that FTS can be 
released from the conjugate via intracellular esterases. It is also apparent that significantly higher 
levels of parent FTS were found in tumor cells treated with PEG5K-S-S-FTS2 conjugate (Figure 
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47). A similar result was found in tumor tissues (Figure 48) in tumor-bearing mice receiving i.v. 
administration of PEG5K-FTS2(L) or PEG5K-S-S-FTS2 conjugate. FTS can be released from the 
PEG5K-S-S-FTS2 conjugate via two different mechanisms: one is direct cleavage of the ester 
linkage adjacent to FTS to generate the parent FTS, the other one involves reduction of the 
disulfide linkage first, followed by cleavage of the ester linkage to generate the parent FTS 
(Figure 51). The fact that significantly greater amounts of parent FTS were released from cells 
treated with PEG5K-S-S-FTS2 would suggest that the latter is the major mechanism for FTS 
release (Figure 51). This is probably because direct release of FTS from PEG5K-FTS2(L) by 
intracellular esterases is relatively ineffective due to the steric hindrance imposed by PEG. On 
the other hand, cleavage of disulfide linkage is a more effective process inside tumor cells due to 
the significantly increased GSH levels in tumor cells [49, 124]. Once released from the conjugate, 
the small molecule intermediate can be effectively hydrolyzed by the intracellular esterases to 
generate the parent FTS (Figure 51). 
 
Figure 51. Proposed mechanism for the release of FTS from PEG5K-FTS2 and PEG5K-S-S-FTS2 
conjugates following intracellular delivery to tumor cells. 
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In vitro cytotoxicity showed that PEG5K-S-S-FTS2 conjugate was significantly more 
effective in inhibiting the proliferation of cultured tumor cells compared to PEG5K-FTS2(L) 
conjugate (Figure 46). The increased cytotoxicity of PEG5K-S-S-FTS2 is most likely due to a 
facilitated release of FTS following inclusion of an additional cleavable disulfide linkage. It is 
interesting to note that PEG5K-SS-FTS2 also exhibited higher levels of cytotoxicity than free FTS 
at low concentrations (Figure 46). This is unlikely due to the surfactant activity of the conjugate 
as PEG5K-SS-FTS2 showed minimal hemolytic activity at even much higher concentrations (data 
not shown). It is possible that PEG5K-SS-FTS2 is more effectively taken up by tumor cells than 
free FTS, which will be further examined in the future. PEG5K-S-S-FTS2 not only retained the 
biological activity well, but also served as an efficient carrier to deliver hydrophobic drug PTX. 
PTX formulated in PEG5K-S-S-FTS2 micelles showed a level of cytotoxicity that was higher than 
that of either Taxol or PTX formulated in PEG5K-FTS2(L) micelles (Figure 48), particularly at 
low PTX concentrations. 
In vivo antitumor study showed that PTX formulated in PEG5K-FTS2(L) micelles were 
significantly more effective  than Taxol formulation in a syngeneic murine breast cancer model 
(Figure 8), which is consistent with our previous report [67]. It is also apparent that inclusion of 
a disulfide linkage in PEG5K-FTS2(L) micellar system led to a further improvement in antitumor 
activity (Figure 49). The improved performance is likely attributed to a more effective cleavage 
of FTS from the conjugate in the tumor tissue, which shall lead to not only enhanced intracellular 
delivery of FTS but also facilitated release of loaded drug following disassembly of micelles. It 
remains to be investigated whether the improved carrier/drug interaction and the reduced CMC 
of the PEG5K-S-S-FTS2 micellar system also contribute to the overall improvement in antitumor 
activity.  
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6.0  SUMMARY AND PERSPECTIVES 
Chemotherapy is the most commonly used cancer treatment. However, the traditional anticancer 
agents are limited by their undesirable properties such as low aqueous solubility and low tumor 
selectivity. Upon intravenous administration, these small molecule drugs are rapidly degraded or 
cleared from systemic circulation. Simultaneously, they are nonselectively widely distributed to 
normal tissues and tumors, causing severe systemic toxicity. Nanomedicines can avoid this 
problem by achieving targeted delivery of anticancer agents to tumor tissues, which is based on 
the exploitation of enhanced permeability and retention (EPR) effect. EPR effect was discovered 
by Maeda and his colleagues about 30 years ago, which is the most important strategy for 
enhancing the delivery of small molecule anti-cancer drugs to tumors. Due to solid tumors tend 
to present with a poorly differentiated vasculature, nanocarriers with a certain size can 
selectively go to tumor tissues. Together with the fact that tumor tissues usually lack functional 
lymphatics and therefore are unable to eliminate extravasated nanocarriers, this allows for 
nanocarriers to accumulate in the tumor tissue. Development of effective nanocarriers will be 
important and beneficial to deliver therapeutic agents in a safer and more efficient manner. They 
can encapsulate water insoluble drugs, protect them from biodegradation and alter their blood 
pharmacokinetic behavior and biodistribution. Currently, a wide range of macromolecular 
delivery systems such as long-circulating liposomes, nanoparticles, polymers and micelles have 
been employed for the development of new cancer therapies. Some of them did present with 
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quite promising therapeutic efficacy and are approved for clinical use, including Doxil 
(liposomal doxorubicin (DOX)), Abraxane (albumin-based nanoparticle containing paclitaxel 
(PTX)), Oncaspar (polyethylene glycol (PEG)-L-asparaginase), Genexol-PM (micellar 
paclitaxel) and so on.  
Among the many studied delivery systems, polymeric micelles have attracted an 
increasing interest because of their simplicity, small sizes, and their ability to solubilize water-
insoluble drugs and accumulate specifically in tumors. For conventional chemotherapy, various 
approaches to achieve dual delivery of small-molecular drugs. The co-delivery of multiple agents 
to tumors could achieve combinatorial effects to enhance therapeutic efficacy and lower the risk 
of resistance by affecting multiple pathways involved in cancer. The development of polymeric 
micelles possessing both biological activities by themselves and the ability to deliver other 
anticancer drugs offers a feasible solution for drug combination cancer therapies. The design of 
polymeric micelles that exhibit antitumor activity can either reduce the side effects caused by the 
encapsulated drug or simultaneously provide a synergistic activity with the loaded drug. 
During my graduate study, I worked on several cohesive projects to develop dual 
functional nanomicellar carriers for the targeted delivery of anticancer drugs for cancer. First, we 
developed PEG-derivatized FTS conjugates, which retained the biological activity of FTS and 
formed small-sized micelles that effectively solubilize a PTX. PTX formulated in this micellar 
system showed a PTX release kinetics that was significantly slower than that of the Taxol. PTX 
formulated in PEG5K-FTS2(L) micelles was more cytotoxic than free PTX in vitro. In vivo, 
PTX/PEG5K-FTS2(L) showed antitumor activity that was more potent than that of Taxol or 
PTX/PEG5K-FTS2(S). PEG5K-FTS2(L) may represent a promising micellar system that could 
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effectively deliver anticancer agents to tumors. Furthermore, it may potentially synergize with 
the co-delivered drugs to enhance overall antitumor activity. 
In addition, efforts were also made to systematically study the SAR of a PEG-FTS based 
dual functional carrier. A structure activity relationship (SAR) study was conducted in four PEG-
FTS conjugates that vary in the molecular weight of PEG (PEG2K vs PEG5K) and the molar ratio 
of PEG/FTS (1/2 vs 1/4). We demonstrated that PEG5K-FTS4 formed the most stable mixed 
micelles with PTX among the four PEG-FTS conjugates. In vivo, PTX-loaded PEG5K-FTS4 led to 
an improved tumor growth inhibitory effect in comparison to PTX formulated in PEG2K-FTS2, 
PEG2K-FTS4, and PEG5K-FTS2 as well as Taxol in a syngeneic mouse model of breast cancer 
(4T1.2).  
In order to further improve the performance of the PEG-FTS-based dual functional 
carrier, a drug-interactive Fmoc motif was introduced into this system. We demonstrated that 
both drug loading capacity and formulation stability were significantly improved by inclusion of 
a drug-interactive Fmoc motif. Pharmacokinetics and biodistribution studies showed that DOX-
loaded PEG5K-Fmoc-FTS2 micelles were able to retain DOX in the bloodstream for a prolonged 
period of time and were highly effective in targeted delivery of DOX to tumors. More 
importantly, PTX- or DOX-loaded PEG5K-Fmoc-FTS2 micelles led to a superior antitumor 
activity over other treatments including drugs formulated in PEG5K-FTS2 micelles in both breast 
cancer and prostate cancer models. PEG5K-Fmoc-FTS2 may represent a promising micellar 
system for effective delivery of anticancer agents to tumors. 
As a dual function carrier, the cleavability of the linkage between PEG and FTS in 
PEG5K-FTS2 conjugate is critical for its biological activity. An improved dual-functional 
micellar carrier composed of a PEG shell and FTS core via a disulfide linkage (PEG5k-S-S-FTS2) 
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was developed. PEG5k-S-S-FTS2 retained the FTS biological activity well, which was attributed 
to an effective release of FTS from the conjugate following intracellular uptake. In addition, 
PEG5k-S-S-FTS2 readily self-assembled into small-sized micelles and formed stable mixed 
micelles with PTX. More importantly, PTX-loaded PEG5k-S-S-FTS2 micelles demonstrated more 
effective therapeutic effects in vivo over Taxol formulation and PTX-loaded PEG5k-FTS2 
micelles. 
PEG-FTS-based micellar systems demonstrated potential as effective and dual-functional 
carriers for poorly water soluble anticancer agents. Despite the promising data, particularly the 
data on in vivo therapeutic efficacy, much remains to be done to further demonstrate their 
potential, particularly more toxicity and pharmacokinetics study. In addition, more systematic 
studies on the structure-activity relationship of polymeric micellar systems are needed to better 
understand the mechanism of drug-carrier interaction and establish a stable micellar system with 
a high drug loading capacity. These studies shall lead to the development of effective delivery 
system for anticancer drug with potential for rapid translation into clinical study. 
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